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1. Introduction 
 
Cancer is the major public health problem and remains the leading cause of death worldwide. 
The United States National Institute of Cancer (NIC) estimates approximately 1.5 million 
people diagnosed with cancer each year (www.cancer.gov). Thus, there exists an urgent need 
for the discovery or development of novel compounds representing antineoplastic effects. 
Despite the incredible effort invested in the development of novel cytostatic and regulatory 
agents, cytotoxic chemotherapy associated with relatively high toxicity remained the only 
option in the treatment of advanced/metastatic cancer over the past few decades. The quest for 
better, more efficacious and less toxic approaches to the delivery of cytotoxic agents has 
intensified. Today, about 60% of cytostatic agents in Western medicine are metabolites of 
naturally occurring compounds (Newman and Cragg, 2007). New methodologies have 
dramatically improved drug screening and synthesis of novel analogs with more favorable 
performance characteristics than their predecessors. Great progress was made in identifying 
and analyzing new anticancer agents with enhanced efficacy while at the same time exerting 
less toxicity. Many of these investigated drugs already showed a broad spectrum of beneficial 
physiological and antineoplastic effects, the latter through induction of apoptosis and 
inhibition of several enzymes of DNA synthesis in a multitude of cancer cell lines. In this 
diploma thesis, the following compounds were investigated for their anticancer activity in 
various human tumor cell lines: 
ABNM-13 is a newly designed N-hydroxy-N`-aminoguanidine. The compound has been 
designed by a 3D molecular space modeling technique aiming at the inhibition of 
ribonucleotide reductase (RR) activity in human HL-60 promyelocytic leukemia cells. 
Treatment with various other compounds have already shown that diminished RR activity 
causes alterations of the dNTP pool balance (Szekeres et al, 1997) and decrease of 
incorporation of labeled cytidine into DNA (Szekeres et al, 1994). 
Digalloyl-resveratrol (DIG) is a novel synthetic ester of the polyhydroxy phenolic substances 
resveratrol (3,4,5-trihydroxystilbene; RV) and gallic acid (3,4,5-trihydroxybenzoic acid; GA). 
Both compounds are naturally occurring agents, which are present in several plants and are 
known to own disease preventive properties in various cancer cell systems (Horvath et al, 
2006; Madlener et al, 2007). 
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Recent investigations have already demonstrated a significant growth inhibiting and RR 
inhibiting effect of DIG in human HT-29 colon cancer cells (Bernhaus et al, 2009). The 
biochemical effects of DIG were investigated in three different human pancreatic cancer cell 
lines. 
Both agents were compared for their cytotoxicity employing growth inhibition and clonogenic 
assays. The induction of apoptosis was quantified using a Hoechst/propidium iodide double 
staining method and cell cycle distribution effects were evaluated by FACS. The question of 
whether these drugs inhibit the in situ activity of RR and/or  affect the steady state 
deoxynucleosidetriphosphate pools (dNTPs), which are the products of RR metabolism, is 
addressed by incorporation of radio-labeled cytidine into DNA of tumor cells and by 
employing a specific HPLC method, respectively. Additionally, the combination effects of 
these compounds were examined. Therefore, agents were applied simultaneously or 
sequentially with clinically well-established anticancer drugs like Cytarabine (Ara-C) or 
Gemcitabine (dFdC). Following western blot analysis displayed a deeper insight into the 
underlying mechanisms of apoptotic and growth inhibiting pathways. 
All investigations provide new information about the biological activities of synthetically 
designed ABNM-13 and DIG, synthesized of the two natural occurring compounds 
resveratrol and gallic acid. Therefore, these agents might contribute to the clinical 
establishment of new combined therapies of human malignancies. 
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2. Literature Survey 
2.1. Ribonucleotide Reductase 
 
In 2010 the discovery of ribonucleotide reductase (RR) celebrated its 50
th
 anniversary 
(Reichard, 2010). Since then it has been proven that disturbance in its allosteric regulation is 
associated with malignant transformation and tumor cell proliferation. RR was therefore 
considered an important target for anticancer agents (Smith and Karp, 2003; Nocentini, 1996). 
2.1.1. Function and Structure 
 
Ribonucleotide reductase (RR) catalyzes the conversion of ribonucleoside diphosphates to 
deoxyribonucleoside diphosphates, which are the basic units for DNA synthesis and DNA 
repair (Kolberg et al, 2004). De novo dNTP synthesis is an exactly regulated reaction; thus, 
RR is the rate-limiting enzyme in that mechanism. Imbalances in dNTP levels or in the 
production of equimolar amounts cause cell death or genetic abnormalities (Reichard, 1988). 
The enzymatic activity of RR proceeds by free radical chemistry; due to the way this radical 
is generated, RR is divided into three different but related main classes. Each class is based on 
a different metal cofactor for radical generation (Nordlund and Reichard, 2006).  
Class I enzymes are mainly found in eukaryotic organisms and can be further divided into 
three subclasses. The human RR is a tetrameric holoenzyme (α2β2) and belongs to Class Ia 
(Stubbe et al, 2003). It consists of a large α2-homodimer, called R1 and of a small β2-
homodimer, called R2 (figure 1). 
R2 harbors an oxygen-linked dinuclear Fe(III) center to create a tyrosyl radical that is 
essential for the transient formation of a thiyl radical in R1.  
R1 is the reductase subunit and contains redox active disulfides that take part in the reduction 
of the substrate. Furthermore it harbors allosteric sites for effector binding and an active site 
for substrate binding (Reichard, 2010; Shao et al, 2006). 
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2.1.2. Multiple Regulations 
 
The activity of RR in mammalian cells can be regulated differently. To provide a balanced 
supply of dNTPs for DNA replication; to achieve this goal, the enzyme is regulated by a 
difficult allosteric regulation. The allosteric sites in the R1 subunit contain an activity site (A-
site), a specificity site (S-site) and a hexamerization site (H-site). 
ATP (activation) and dATP (feedback inhibition) bind to A-site for regulating overall enzyme 
activity. Binding of allosteric effectors (dATP, ATP, dTTP, dGTP) to S-site ensures correct 
proportion of dNTPs. ATP binding to the third bonding-site catalyzes the rearrangement of 
the active R16R26 hexamer of RR (Shao et al, 2006). 
Enzyme activity can also be regulated by R2 protein level. During the S-phase of the cell 
cycle, equal amounts of dNTPs are required. Therefore, the quantities of RR/transcription of 
the subunits in proliferating cells are closely linked with the cell cycle. While R1 shows 
constant expression level throughout the cell cycle, R2 accumulates in early S phase and 
afterwards rapidly degrades (Thelander et al, 1985). 
 
2.1.3. A target for cancer chemotherapy 
 
RR is responsible for the appropriate supply of the four dNTPs for DNA synthesis and is 
therefore an essential enzyme in the cell proliferation mechanism as already mentioned. 
  
 
 
a b 
Figure 1: E. coli R1 protein dimer with C-terminal end of R2 (a). E. coli R2 protein dimer structure (b) 
(Shao et al, 2006). 
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Inhibition of RR decreases dNTP amounts, de novo DNA synthesis and DNA repair and thus 
causes apoptosis and cell cycle arrest (Nocentini, 1996). 
Cancer cells need great amounts of dNTPs for their increased cell proliferation. Hence, RR 
activity is increased and is in contrast associated with decreased adaptability and 
responsiveness. RR is therefore a more sensitive target for cytotoxic agents in tumor cells than 
in native cells (Nocentini, 1996). 
Tanaka et al described a new RR gene, p53R2 that is directly regulated by p53 transcription 
factor. p53 tumor suppressor protein regulates cell cycle by arresting at the G1/S regulation 
point or by initiating apoptosis. Expression of p53R2, a R2 homolog, is induced by γ-
irradiation, UV or DNA damage (Tanaka et al, 2000). 
Various investigations showed that two different pathways maintain the balanced supply of 
dNTPs: one way through the well-known R2 activity during the S/G2 phase and the other way 
through p53R2. In that case, dNTPs are required for DNA repair in a p53-dependent manner 
(Yamaguchi et al, 2001; Lozano et al, 2000). 
These findings increased the relevance of p53R2 in human cancer development. Various 
regulation mechanisms provide different targets enabling the development of subunit-specific 
agents for different applications and effects. For example, specific inhibition of p53R2 
increases the sensitivity of tumor cells to cytotoxic agents (Lin et al, 2004). 
 
2.1.4. Human RR inhibitors 
 
For the last decades, various specific inhibitors of RR have been discovered. Some of them 
have found clinical applications as anti-tumor agents; others are still in clinical trials. RR 
inhibitors are distinguished between their chemical structure and properties and between their 
different targets and mechanisms of action. Inhibiting effects are caused by gene expression 
regulation or by protein inactivation. 
Gemcitabine (dFdC) as well as Cytarabine (Ara-C) are substrate analogs that inactivate the 
enzyme by inhibition of R1 protein. Both inhibitors are first modified by deoxycytidine kinase 
(dCK) at the carbon 2` of ribose or arabinose and therefore recognized by RR as natural 
purine or pyrimidine nucleosides. Ara-C is modified to ara-CDP and ara-CTP while dFdC is 
further metabolized to dFdCDP and dFdCTP. Interaction with the active site of R1 leads to 
6 
 
deficient products that inactivate RR (van der Donk, 1998; Shao et al, 2006). The inhibition of 
RR is followed by a decrease of dNTPs and in further consequence by competition between 
normal dCTP and dFdCTP/ara-CTP for incorporation into DNA, thus inhibiting DNA 
polymerase. All these effects lead to termination of DNA elongation and finally to apoptosis 
(Faderl et al, 2002). 
Another category of inhibitors inactivates RR by destroying the tyrosyl radical. These radical 
scavengers target R2 or p53R2 subunits (e.g. Hydroxyurea or Trimidox) (Lassmann et al, 
1992; Szekeres et al, 1994). 
Various studies proved that combinations of subunit-specific inhibitors result in synergistic 
inhibition of cell proliferation. Such treatment plans may even avoid drug resistance of cancer 
cells (Szekeres et al, 1997). 
Other investigations revealed the combination of genotoxic chemotherapeutic agents with 
specific-R2 subunit inhibitors as a promising treatment regimen (Strand et al, 2002; 
Cooperman; 2003). 
 
2.2. Cancer 
 
2.2.1. Carcinogenesis - a multistep process 
 
Carcinogenesis describes the process of the transformation of normal cells into cancer cells. 
Cancer develops due to the loss of growth and proliferation regulation of cells. An aberrant 
cellular regulation is often influenced by exposure to carcinogens, which results in genetic 
damages. Two important groups of genes are involved in the on-set of cancer: tumor-
suppressor genes normally cause the constraint of cell growth and cell survival while proto-
oncogenes promote the growth. A third group named caretaker genes normally protect the 
genome integrity by repairing or preventing DNA damages (Molecular cell biology/Lodish et 
al (2008)-6
th
 ed.; p.1107). 
Loss-of-function mutations in tumor-suppressor genes or caretaker genes lead to unregulated 
cell proliferation or to accumulation of mutation while gain-of-function mutations transform 
proto-oncogenes into oncogenes allowing unregulated cell proliferation (Molecular cell 
biology/Lodish et al (2008)-6
th
 ed.; 25.2). 
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The development of cancer requires an accumulation of mutations (Barrett, 1993), so cancers 
mainly establish later in life. Carcinogenesis is a multistep process and can be divided into 
three different periods: initiation, promotion and progression. 
Initiation phase of carcinogenesis is characterized by an irreversible DNA damage being a 
result of extrinsic or intrinsic cytotoxic exposures. Quiescent initiated cells enter promotion- 
phase due to influence of non-carcinogenic compounds which results in clonal expansion of 
cells. Hennings et al revealed the reversibility of promoting effects, which seems to depend on 
epigenetic mechanisms (Hennings et al, 1993). Promotion phase develops a benign foci 
consisting of pre-neoplastic cells. The conversion of pre-neoplastic cells into malignant 
cancer cells is called progression. Benign tumors and malignant neoplasms essentially differ 
in morphology, invasiveness differentiation and growth (Barrett, 1993). 
 
2.2.2. The hallmarks of cancer 
 
Hanahan and Weinberg described six fundamental cellular properties which are altered during 
carcinogenesis (figure 2) (Hanahan and Weinberg, 2000). All these physiological alterations 
are responsible for the development of a destructive cancer phenotype. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Six fundamental properties in cell physiology causing 
cancer (Molecular cell biology/ Lodish et al (2004)-5
th
 ed.) 
8 
 
Cancer cells are proliferating without requiring external signals, they fail to sense cell cycle 
regulation, they are moving in other tissues and induce the development of blood vessels into 
the carcinogenic tissue (Molecular cell biology/Lodish et al (2008)-6
th
 ed.; p.1108). 
 
2.2.3. Cell cycle and Cancer 
 
The term cell cycle describes serial events leading to subsequent cell division and two 
identical products. The cell cycle in mammalian cells is usually divided into four distinct 
phases: G1 (gap phase 1), S (phase of synthesis), G2 (gap phase 2), M (mitosis) (figure 3). 
To achieve an accurate cell replication and segregation a multiple checkpoint control 
mechanism prevents abnormalities in cell cycle progression. Altered activation of these 
checkpoint-proteins may lead to the development of abnormal cell growth, differed gene 
expression levels and finally cancer cells (Meeran and Katiyar, 2008). 
The whole preparation for cell division is done during the interphase that includes G1-, S- and 
G2-phase. Furthermore, cells can stop in G1, before DNA replication is started and pause in 
the so-called G0 phase. Entering quiescent G0 state depends on external and regulatory signals 
(van den Heuvel, 2005). 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 3: Eukaryotic cell cycle (simplified) (Molecular 
cell biology/ Lodish et al (2008)-6
th
 ed.) 
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Chromosome replication occurs in the S-phase; that requires cell growth and DNA synthesis 
in the preceded G1-phase. In the second gap G2-phase, cells are preparing for mitosis in the 
following so called M-phase (Vermeulen et al, 2003). 
 
2.2.3.1. Cell cycle regulation by cyclin-dependent kinases (CDK) 
 
For coordinating the different events in the cell cycle, specific regulatory proteins are 
activated at specific moments of the division cycle. These controllers are heterodimeric 
cyclin-dependent kinases (CDKs). The expression level of CDKs is stable throughout the 
whole cell cycle, compared to the cyclins, the regulatory subunits of the kinases. Cyclin 
amounts in the cell differ during the division cycle, thereby affecting CDKs kinase activity. 
There are different types of cyclins for every single phase in the cell cycle. (Vermeulen et al, 
2003). 
CDKs are associated with specific cyclins and form cyclin-CDK complexes (Murray, 2004). 
These activated complexes regulate multiple downstream proteins involved in the cell cycle 
progression by phosphorylation (Morgan, 1995). 
The cyclin-CDKs can be divided into three interphase kinases: CDK2, CDK4, and CDK6. 
Furthermore one mitotic CDK is known; the so-called CDK1 or cdc2. Cell-cycle related 
cyclins include type A, B, D and E (Meeran and Katiyar, 2008). 
Cyclins D and E contain specific protein sequences for efficient proteolysis at the end of 
every cycle phase (Rechsteiner and Rogers, 1996). Hence they can periodically activate the 
kinases. 
CDKs can also be regulated by inhibitory proteins (CKI), which have high affinity for CDKs 
or cyclin-CDK complexes. Thus, CDKs are modulated by two different classes of inhibitors: 
the INK4 and Cip/Kip families. p16, a member of the INK4 family inactivates G1 CDKs, and 
forms a stable CDK-CKI complex preventing cyclin-D association (Vermeulen et al, 2003). 
Deregulation of cyclin-CDK complexes and therefore disorder of the cell cycle results in 
permanent cell proliferation, which may lead to the development of cancer. 
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2.2.3.2. Cell cycle regulation by checkpoint proteins 
 
Controlling the eukaryotic cell cycle, multiple layers of regulation mechanisms are involved. 
These additional building blocks of the regulatory system are termed checkpoint kinases. 
With that difficult control system, cells react on DNA damage by interrupting cell cycle 
progression or by apoptosis. Deregulation of the key regulatory molecules is associated with 
increased cancer risk (Meeran and Katiyar, 2008). In the following a short overview of the 
three major checkpoints is given: 
 
S-phase checkpoint 
The intra-S-phase checkpoint network ensures that broken or damaged DNA is recognized by 
the control system. An important pathway causes the activation of ATM/ATR-Chk1 cascade. 
According to the type of damage Chk1 is phosphorylated by ATM or ATR, leading to further 
phosphorylation and down regulation of the Cdc25A phosphatase (Kastan and Bartek, 2004). 
That inhibition inactivates the mitotic cyclin E-CDK2 complex, which is essential for 
proceeding in S-phase (Falck et al, 2002). 
 
D	A-damage checkpoint 
G1/S checkpoint kinases prevent copying of damaged DNA by arresting the cell cycle until 
the damaged bases are exchanged. Occurrence of DNA damages at that checkpoint seems to 
be a crucial step to the onset of cancer (Pinto et al, 2005; Sherr and Roberts, 1999). This 
checkpoint is mediated by the ATM/ATR-Chk1/Ch2-Cdc25A pathway. UV-damaged DNA 
activates ATM kinases which phosphorylates Chk2. Activated Chk2 phosphorylates Cdc25A, 
initiating its degradation. DNA damage due to γ-irradiation activates ATR and Chk1, which 
also leads to Cdc25A ubiquitination. The degradation of Cdc25A results in G1/S-arrest 
(Kastan and Bartek, 2004). 
The p53 tumor suppressor represents another important regulatory protein in G1 checkpoint. 
Normally p53 transcription factor is extremely unstable and rapidly degraded. 
Phosphorylation of p53 by ATM/ATR (Ser
15
) and by Chk1/Chk2 (Ser
20
) inhibits degradation, 
promotes accumulation, and causes arrest in G1/S phase. A key target of the transcription 
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factor p53 is a gene encoding for p21
CIP
 - a CKI of the Cip/Kip family - that inhibits 
cyclinE/CDK2 kinase and leads to inhibition of G1/S transition until damaged DNA bases are 
repaired (Meeran and Katiyar, 2008). 
Besides its regulating mechanism in the cell cycle, p53 can also activate the expression of 
genes initiating apoptosis. These ambivalent properties may provide the observations that in 
nearly all cancer cells the p53 gene is mutated in both alleles (Molecular cell biology/Lodish 
et al (2008)-6
th
 ed.; p. 891). 
 
G2/M-checkpoint 
 
G2/M-checkpoint proteins sense DNA damages during G2-phase or damages without proper 
repair in G1- or S-phase and prevent cells from initiating mitosis. Thereby mitosis promoting 
cyclinB/CDK1 (cdc2) kinase is inhibited by Chk1/Chk2 and/or by p38 via inhibition and 
degradation of Cdc25 phosphatase family proteins (Kastan and Bartek, 2004). 
BRCA1 and p53 were discussed to be essential for the regulation of G2/M-checkpoint by 
targeting p21
CIP
, which causes dissociation of the cyclinB/CDK1 complex (Nyberg et al, 
2002; Taylor and Stark, 2001). 
 
2.2.4. Cell death programs 
 
Programmed cell death is an essential process in maintenance and formation of tissues, during 
immune regulation or homeostasis. An accurate regulatory system performs numerous events 
leading to fatal morphological changes and ultimately to death. Due to differences in 
regulation and morphology, programmed cell death can be divided into apoptosis, necrosis 
and autophagy. 
 
2.2.4.1. Apoptotic cell death 
 
Apoptotic cells are marked by well-defined morphological changes: cells shrink, condense 
and fragment. Released apoptotic bodies are finally engulfed by phagocytes and surrounding 
cells.  
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The apoptotic regulatory system comprises two important protein families: on the one hand 
the Bcl-2 family, which controls mitochondrial integrity and on the other hand the caspases 
(cysteinyl aspartate-specific proteases), which execute the apoptotic process (Youle and 
Strasser, 2008; Fuentes-Prior and Salvesen, 2008). 
Human apoptotic caspases are homodimers and can be divided into executioner (caspase-3, -
6, -7) and initiator (caspases-2, -8, -9, -10) caspases. Proteins are initially synthesized as 
procaspases and proteolytically cleaved into the active protein. Among other intrinsic or 
extrinsic regulatory pathways, the Bcl-2 family regulates processing of the proproteins by 
antagonizing pro- (e.g. Bax) and anti- (e.g. Bcl-2) apoptotic Bcl-2 family members. Thereby 
the Bcl-2 family controls the release of mitochondrial cytochrome c. Released cytochrome c 
binds to Apaf-1 (apoptotic protease activating factor) and starts and initiates the caspase 
cascade resulting in cell death (Duprez et al, 2009). 
 
2.2.4.2. 7ecrotic cell death 
 
Necrotic cell death usually results from tissue damage and seems to be an accidental and 
uncontrolled cell death. Krysko et al characterized necrosis by the absence of cytochrome c 
release, proteolytic processing of caspases and DNA fragmentation (Krysko et al, 2008). That 
process exhibits specific morphological changes: cells are swelling and bursting, and release 
their intracellular content, which provokes inflammatory reactions. 
Investigations showed that in certain conditions strictly regulated pathways might promote 
necrosis, initiated by various stimuli. Necrosis may act as a back up for apoptotic cell death: 
hampering caspase pathways, necrosis may ensue instead (Duprez et al, 2009). 
 
2.2.4.3. Autophagic cell death 
 
Autophagy describes a catabolic process by which cells degrade and recycle cellular 
components (e.g. aged organelles). Materials are enveloped by plasma membranes and the 
internalized components are degraded in lysosomes. Precursors of lysosomes are 
autophagosomes, which are provided with a double-membrane. In contrast to apoptosis the 
cytoskeleton in autophagic cells remains intact.  
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Massive autophagy can result in cellular dying, therefore a connection between autophagy and 
necrotic or apoptotic cell death may exist (Maiuri et al, 2007). 
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2.3. Pancreatic Cancer 
 
Pancreatic cancer is a very aggressive malignant neoplasm of the pancreas. Exocrine tumors 
are the most common pancreatic carcinomas; about 95% of these pancreatic malignances are 
adenocarcinomas. Endocrine tumors make up about 1% of total cases (Yao et al, 2007). 
 
2.3.1. Epidemiology and Etiology 
 
Epidemiology 
Approximately 270,000 new cases of pancreatic cancer occurred worldwide in 2008 
(http://info.cancerresearchuk.org). Cancer of the pancreas is the fourth (entweder-oder!) most 
common cause of cancer death in Western countries. 80-90% of these cases are diagnosed in 
the non-resectable stage (Rosewicz et al, 1997; Yeo et al, 1999). Therefore, pancreatic cancer 
has a poor prognosis and its survival rate beyond five years is only about 3% (Niederhuber et 
al, 1995). 
Cancer of the pancreas occurs in over 80% of cases in individuals between 60 and 80 years of 
age (Gold et al, 1998). Furthermore, it is more common in males than in females, possibly due 
to different lifestyles or occupational risk factors (Ahlgren et al, 1996). The highest incidence 
of pancreatic cancer in men has been detected in New Zealand Maoris and American black 
populations (Boyle et al, 1989). 
 
Etiology 
The causes of pancreatic cancer are ranging from cystic fibrosis – caused by a genetic 
mutation – to purely environmental diseases. Two large studies (Lichtenstein et al, 2000) 
showed that environmental factors are the most important causes of most types of cancer. 
Smoking is the most common known risk factor causing about 25% of all pancreatic tumors. 
Compared to non-smokers smokers have a two-fold increased risk of pancreatic cancer. 
Numerous epidemiological studies revealed a significant correlation between the duration and 
intensity of cigarette smoking and the risk of pancreatic cancer (Silverman et al, 1994; Doll et 
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al, 1994; Lin et al, 2002). Furthermore, it is reported that the risk of pancreatic cancer in 
smokers is second only to lung cancer in men and women (Neuget et al, 1995). 
In 2003, Calle et al showed in a cohort study of US adults that caloric consumption and/or 
obesity could be a risk factor for pancreas cancer. High intake of cholesterol and animal fat 
increases the risk, while intake of dietary fibre and Vitamin C decreases the risk of pancreatic 
cancer. 
Several studies revealed an association of chronic pancreatitis and long-standing type II 
diabetes with an increased risk of pancreatic cancer (Lowenfels et al, 1999; Huxely et al, 
2005). 
The role of alcohol in the etiology of pancreatic cancer was investigated by several studies. 
However, most studies failed to establish a link between alcohol intake in moderate amounts 
and increasing pancreatic cancer risk (Lowenfels et al, 2006; Lin et al, 2002). 
In recent years epidemiological studies have confirmed that several inherited disorders are 
linked with pancreatic cancer. Pancreatic cancer is seen in some breast cancer families with 
BRCA1 and BRCA2 mutations (Johannson et al, 1996; Phelan et al, 1996). Epidemiological 
studies have confirmed that people with a family history of pancreatic cancer have a higher 
risk of this malignancy (Ghadirian et al, 2003). 
Some studies assumed that people infected with Helicobacter pylori - listed as a proven 
carcinogen by the International Agency for Research on Cancer - appeared to be at high risk 
of pancreatic cancer. However, the association between pancreatic cancer and H. pylori 
infection is not regarded as proven (Jesnowski et al, 2010; Lowenfels et al, 2006). 
 
2.3.2. Treatment 
 
Pancreatic cancer patients often do not experience symptoms such as weight loss, pain or 
jaundice. In these cases the diagnosis may not be suspected; therefore unfortunately only 10-
20% of patients present resectable diseases at the time of diagnosis (Loos et al, 2008). 
For 80-90% of patients, chemotherapy and/or radiotherapy remain the only treatment 
option(s). A study of Glimelius et al showed that chemotherapy could prolong survival, 
palliate symptoms and improve quality of life in about one-third of the patients. The average 
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survival rate of the chemotherapy group in the study was 2.5 to 6 months (Glimelius et al, 
1996).  
 
Surgical Treatment 
Radical surgical resection may be suggested as a curative or as a palliative treatment to 
improve the patient`s quality of life. A surgery remains the only treatment offering an 
advantage in terms of overall survival (5-year survival range, 15-25%) (Di Marco et al 2010; 
Yeo et al, 2002) 
The first successful resections (pancreatoduodenectomy or Whipple procedure) were 
performed by Walter Kausch in 1912 and Allan Whipple in 1934 (Whipple et al, 1935; 
Pugliese et al, 2008; Strasberg et al, 1997). Due to new advances in technology and 
techniques during the last decades, laparoscopic surgeries have opened new gates in a range 
of applications in patients with pancreatic diseases. The first laparoscopic 
pancreatoduodenectomy was described in 1994 (Gagner et al, 1994; Gagner et al, 1997; 
Dulucq et al, 2005). 
The Whipple procedure involves the removal of the gallbladder, common bile duct, part of the 
duodenum and the head of the pancreas. 
 
Radiation therapy 
Radiotherapy for pancreatic carcinoma is normally performed as chemoradiotherapy (CRT). 
Several randomized controlled trials showed that adjuvant or additive CRT prolongs survival 
by improved local tumor control (Kalser et al, 1985). 
Moertel et al already demonstrated in early studies that combined CRT followed by additive 
chemotherapy was superior to radiotherapy alone (Moertel et al, 1981; Moertel et al, 1961). 
 
Chemotherapy 
Most patients with advanced pancreatic cancer cannot have their tumors removed surgically. 
In that case, palliative chemotherapy is given to improve quality of life, prolong survival and 
to reduce the size of the tumor. 
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5-Fluorouracil 
Although pancreatic cancer cells are mainly resistant to chemotherapy, 5-fluorouracil (5-FU) 
has been shown to be superior to no treatment arms in adjuvant therapy trials. In several 
studies it has also been shown that various combination regimens with 5-FU achieve a modest 
benefit compared to no treatment arms in palliative therapy trials (Neoptolemos et al, 2003; 
Bakkevold et al, 1993). These combination regimens did not show any significant survival 
benefit compared with single-agent 5-FU (Cullinan et al, 1990). 
5-FU is an S-phase-specific, fluorinated pyrimidine that is metabolized intracellulary to its 
active form fluorodeoxyuridine monophosphate (FdUMP) via the de novo pyrimidine 
pathway (Malet-Martino et al; 2002). 
 
Gemcitabine 
During the 1990s multiple clinical studies have demonstrated the benefit of gemcitabine 
(dFdC) for pancreatic cancer compared with 5-FU (Sultana et al, 2010; Burris et al, 1994). 
Gemcitabine (2`,2`-difluorudeoxycytidine; a pyrimidine metabolite; figure 4) is an S-phase 
nucleoside cytidine analogue and is involved in three different mechanisms: it competes for 
incorporation into DNA, it prevents DNA repair and it undergoes self-potentiation (Huang et 
al, 1991). 
 
 
 
 
 
 
 
Since its approval for use in 1996, dFdC is indicated as first-line treatment for patients with 
advanced pancreatic cancer. Phase I and II studies have demonstrated a 5-11% response rate 
 
Figure 4: Structure of Gemcitabine 
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for advanced pancreatic cancer. Gemcitabine produced a median survival rate of 5.7-6.3 
months (Burris et al, 1997; Carmicheal et al, 1996).  
Recent phase I and II trials showed the effectiveness of the dFdC fixed-dose rate regimen 
(FDR) (Gelibter et al, 2005). However, a confirmatory phase III trial failed to show an 
improvement in the overall survival of the FDR regimen (Poplin et al, 2006). Furthermore, 
recent phase II studies demonstrated the efficacy of dFdC-combined regimens, but none of the 
randomized phase III studies confirmed an improvement of the overall survival compared to 
dFdC alone (Banu et al, 2007). 
To sum up, it can be said that neither dFdC nor dFdC in combination with various drugs (5-
FU, capecitabine, platinum compounds) have significantly improved the prognosis. The 
optimal chemotherapeutic drug or dosing regimen has not been established yet. 
Recent investigations examined new molecular-targeted therapies alone or in combination 
with cytotoxic agents. Epidermal growth factor receptor (EGFR) and HER2/neu in pancreatic 
cancer have important key roles in the activation of main signaling pathways. All these 
pathways lead to activation of genes involved in apoptosis, cell proliferation and 
differentiation. EGFR and HER2/neu are frequently overexpressed in solid neoplasms 
including human pancreatic carcinoma. Therefore targeting the dysregulation of these 
transmembrane proteins with monoclonal antibodies directed against the extracellular ligand-
binding domain might exert an antitumor effect (Potti et al, 2003; Yamanaka et al, 1993). 
It is anticipated that further investigations will test new target biological agents or new 
combinations of dFdC. Cui et al showed that resveratrol, a phytoalexin inhibits the 
proliferation of pancreatic cancer cells (Cui et al, 2010). These results are in agreement with 
another previous study by Bernhaus et al indicating that KITC, a new resveratrol derivate, 
shows antitumor effects in human pancreatic cells (Bernhaus et al, 2009). 
 
2.3.3. In vitro cell systems 
 
AsPC-1 
The human AsPC-1 cell line was derived from nude mouse xenografts initiated with cells 
from the ascites of a patient with pancreatic cancer. The patient was a 62-year-old Caucasian 
woman with an adenocarcinoma in the pancreas (http://www.atcc.org). 
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BxPC-3 
The human BxPC-3 cell line was derived from a 61-year-old female patient with an 
adenocarcinoma in the pancreas. The cells do not express the cystic fibrosis transmembrane 
conductance regulator (CFTR) (http://www.atcc.org). 
 
PA	C-1 
The human PANC-1 cell line was derived from a 56-year-old male Caucasian patient with an 
epithelioid carcinoma in the pancreas (http://www.atcc.org). 
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2.4. The Leukemias 
 
2.4.1. Definition and Categorization 
 
Leukemia is cancer that starts in blood and bone marrow. It causes an abnormal increase of 
white blood cells, which enter the bloodstream. Leukemia, the most common blood cancer, is 
part of a group of diseases called hematological neoplasms. 
Normally cellular blood components derive from pluripotent hematopoietic stem cells. The 
development of mature peripheral blood cells requires differentiation and a controlled 
proliferation of stem cells. Approximately 10
11
-10
12
 new white blood cells, red blood cells 
and platelets are produced daily. 
Leukemia is the result of certain mutations in the DNA. These genetic events cause activation 
of oncogenes or deactivation of tumor suppressor genes whereby progeny of the stem cells no 
longer differentiate and proliferate normally. 
The leukemias can be grouped according to which kind of blood cell is affected (lymphoid 
versus myeloid) and according to the progress of disease. The acute leukemias are 
characterized by rapid increase of immature abnormal myeloid (in acute myeloid leukemia; 
AML) or lymphoid (in acute lymphoid leukemia; ALL) cells in the bone marrow. Due to the 
rapid uncontrolled accumulation and progression of the immature cells, symptoms in acute 
leukemias are quicker perceptible than in chronic leukemias. Malignant cells immigrate into 
the bloodstream and into other organs of the body. Symptoms include anemia, petechia, 
infection and bleeding (www.cancer.gov). 
Chronic leukemia is often found during a routine check-up because untreated people can live 
many years without any symptoms. It is characterized by an excessive proliferation of 
relatively mature blood cells. The still abnormal cells are accumulated in a higher rate than 
normal cells, resulting in the prevalence of abnormal white blood cells, which are genetically 
unstable. Due to the progression of the malignant clones, people get symptoms and the 
disease resembles acute leukemia. The chronic leukemias can also be subdivided into chronic 
myeloid leukemias (CML) and chronic lymphocytic leukemias (CLL). 
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2.4.2. Epidemiology and Etiology 
 
Epidemiology 
Leukemia comprises about 3% of approximately seven million cancer deaths a year. It is the 
most common form of cancer among children age <15 years. Approximately 76% of all cases 
comprise acute lymphocytic leukemia whereas only 15-20% of diagnoses represent AML 
(Deschler and Lübbert, 2006). AML is therefore rather a disease for later adulthood with a 
median age of 65 years (Forman et al, 2003). 
Over the past 20 years, a slight decrease in the incidence and mortality rates for leukemia was 
observed. Although there are remarkable improvements in the younger age group, the relative 
survival rate for older patients continue to be poor (Redaelli et al, 2003). 
 
Etiology 
The different subtypes of Leukemia have different risk factors. The somatic mutations of the 
DNA, as discussed below, may be the result of exposure to a high level of (ionizing) radiation 
or carcinogenic substances. For example, Preston et al confirmed an excess of leukemia 
incidence and mortality in the group of Japanese atomic bomb survivors (Preston et al, 1994, 
2004). 
Ben-David et al showed that viruses such as RNA retroviruses cause neoplasms, including 
leukemia (Ben-David et al, 1991). The first identified human retrovirus, human T-
lymphotropic virus type I (HTLV-I) is associated with lymphocytic leukemia (Bittencourt et 
al, 2006). However, it has not been demonstrated yet, that either a DNA- or RNA-based virus 
alone causes AML (Deschler and Lübbert, 2006). 
Chronic exposure to chemicals, such as benzene, has been reported to increase the risk of 
developing AML (Savitz et al, 1997). Alkylating chemotherapeutic agents are also associated 
with an increased risk of AML (Le Beau et al, 1986). 
Genetic or congenital disorders increase the risk of developing acute leukemia (Pui et al, 
1995). Studies of twins have demonstrated this predisposition. Chromosomal abnormalities, 
such as Down syndrome have an increased likelihood of AML (Xavier and Taub, 2010). 
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2.4.3. Treatment 
 
Normally Leukemia is diagnosed by an examination of the bone marrow or by the comparison 
of repeated blood counts. The aim of treatment is to accomplish complete remission, which 
means the complete regeneration of the bone marrow and the removal of leukemia cells from 
the blood. In most cases, the disease is treated with different regimens of multi-drug 
chemotherapy. Sometimes radiation therapy or bone marrow transplantations are applied to 
leukemia treatment (www.cancer.gov). 
 
Acute Leukemia 
Initially, it is essential to differentiate between AML and ALL. In ALL, the standard 
chemotherapy regimen for adult comprises prednisolone, vincristine and an anthracycline. For 
children the drug therapy may include L-asparaginase. In children, the survival rate is close to 
90% whereas in adults only 38% of patients can be cured (Pieters et al, 2011). The 
performance and the effectivity of bone-marrow transplantation remains a controversial 
discussed topic. 
In AML, the cornerstone of induction therapy is the Ara-C. Standard-dose cytarabine for 7 
days combined with an anthracycline (e.g. daunorubicin) for 3 days induces a complete 
remission in approximately 70% of patients (Robak et al, 2009). 
 
Chronic Leukemia 
The treatment of chronic leukemia rather focuses on alleviating symptoms than on healing up 
the disease. Treatment is normally started when symptoms and blood counts get worse and 
when quality of life is affected. 
Currently, several effective combination chemotherapy plans showing a high response rate 
have been developed. Eichhorst et al reported that the combination regimen of anticancer 
drugs, such as fludarabine plus cyclophoshamide (FC), have longer progression-free survival 
(48 months) than treatment with single agents (20 months) (Eichhorst et al, 2006). A recent 
study supported the concept of synergistic combination chemoimmunotherapy of three agents. 
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Fludarabine and cyclophosphamide in combination with rituximab, a class I chimeric anti 
CD-20 antibody, revealed promising high complete remission rates (Keating et al, 2005). 
Currently, there is no evidence that any described treatment regimens are curative. Patients 
relapse and afterwards develop resistance to the chemotherapeutic agents (Rai et al, 2003). 
Therefore, further approaches must take into account the balance between the increased risk 
for dying of stem-cell transplantation (SCT) in chronic lymphocytic leukemia and the 
potential to cure this disease (Gribben et al, 2008). 
 
2.4.4. In vitro cell system 
 
The human HL-60 is an acute promyelocytic leukemia cell line (APL) derived by Collins et 
al. Peripheral blood leukocytes were obtained from a 36-year-old Caucasian woman with 
acute promyelocytic leukemia (http://www.atcc.org). 
HL-60 cells are representing a subtype of AML. This leukemia is a highly malignant 
neoplasm and characterized by an inhibition of granulocytic differentiation and by a 
chromosomal translocation causing a rearrangement of the retinoic acid receptor α (RARα). In 
over 98% of cases of APL the RARα gene on chromosom 17 is fused on the promyelocytic 
leukemia gene (APL) on chromosom 15-translocation t(15; 17)(q21; q22). The RARα-APL 
fusion protein binds to specific binding sites on DNA, stopping transcription and granulocytic 
differentiation (Vitoux et al, 2007). At the moment all-trans retinoic acid (RA) or arsenic 
trioxide are the mainstays for treatment of APL. These compounds target RARα-PML hybrid 
protein and inhibit its effect on the DNA of tumor cells. 
Recent preclinical studies evaluate new drugs, alone or in combination (e.g. with 
anthracyclines) to treat this disease (Vitoux et al, 2007). 
24 
 
 
2.5. AB7M-13 
 
ABNM-13 (N-hydroxy-2-(anthracene-2-yl-methylene)-hydrazinecarboximidamide) is a novel 
N-Hydroxy-N'-aminoguanidine. 
Modern drug design uses qualitative and quantitative structure-activity relationship (QSAR) 
studies as an approach to find relationships between chemical structures or structure-related 
properties and biological activities of distinct compounds. Based on the prediction of the best 
QSAR model, we synthesized 13 novel compounds (ABNM-1 to ABNM-13) with potential 
RR inhibitory capacities. Five of these agents were active in human HL-60 promyelocytic 
leukemia cells and ABNM-13 was chosen as lead substance because of its pronounced 
inhibitory effects. 
ABNM-13 represents an unknown compound with ambitious expectations effecting in cancer 
cell systems. 
 
 
 
 
 
 
 
 
Figure 5: Structure of AB7M-13 
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2.6. DIG 
 
Digalloylresveratrol (figure 6) (DIG; MW=532.47) is a novel synthetic ester of the 
polyhydroxy phenolic substances resveratrol (3,4,5-trihydroxystilbene; RV) and gallic acid 
(3,4,5-trihydroxybenzoic acid; GA). The compound was first synthesized and provided by Dr. 
Trimurtulu and co-workers, Laila Impex Research Center, Vijayawada 520 007, India 
(Gangaraju et al, 2006, US Patent # 7026518). 
Gallic acid can be found in various natural products such as pineapples, strawberries, sumac, 
tea leaves, grapes, bananas, gallnuts, apple peels, lemons, red and white wine (De Beer et al, 
2003; Sun et al, 2002; Wolfe et al, 2003). Resveratrol is a phytoalexin found in several plants, 
including mulberries, peanuts and grapes (Baur et al, 2006). Both naturally occurring 
compounds are probably responsible for a phenomenon known as the “French Paradox“. The 
latter is the fact that incidence of heart infarction in France is significantly lower (40%) than 
in other European countries or the USA (Renaud and De Lorgeril, 1992). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6: Chemical structures of (A) gallic acid (GA) and 
(B) digalloylresveratrol (DIG) (Madlener et al, 2010) 
26 
 
 
In Addition, the excellent radical scavenging activity of resveratrol and gallic acid was 
determined by several studies (Isuzugawa et al, 2001; Salucci et al, 2002; Horvath et al, 
2005). It has been shown that RV and GA induce differentiation and programmed cell death 
in a variety of tumor cell lines (Kawada et al, 2001). Both compounds were identified as 
effective inhibitors of the enzyme ribonucleotide reductase (RR) (Madlener et al, 2007). 
According to the promising cytotoxic effects of the single compounds, DIG was synthesized, 
consisting of two molecules gallic acid and one molecule resveratrol.  
Bernhaus et al showed that a combination of resveratrol and gallic acid (ratio 1:2) inhibited 
the growth of HT-29 colon cancer cells less than DIG. Furthermore, it was demonstrated that 
DIG led to an inhibition of the RR (Bernhaus et al, 2009). 
In fact, in HL-60 cells the inhibition of cell proliferation by DIG exceeded that of GA by 10-
fold (Madlener et al, 2007). It was also demonstrated that the pro-apoptotic property of 10µM 
DIG is about 10-times higher than 20µM GA. DIG also showed a much higher apoptotic 
activity than RV. These results may support the conclusion that the RV backbones, to which 
the galloyl-residues are connected, are responsible for the determined synergistic effects 
(Madlener et al, 2010). 
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3. Materials and Methods 
3.1. Chemicals and supplies 
 
AB7M 1-13 were synthesized and provided by the Department of Pharmaceutical Sciences, 
Birla Institute of Technology, Mesra, India. Structural formulas are shown in figure 1. 
Cytarabine (Ara-C), Resveratrol (3,4,5-trihydroxystilbene; RV) and solvent DMSO were 
obtained from Sigma-Aldrich GmbH, Vienna, Austria and were of highest purity available.  
Gallic acid (3,4,5-trihydroxybenzoic acid; GA) was purchased from SIGMA, Vienna, 
Austria. Gemcitabine (dFdC) was obtained from ACTAVIS Generica, Austria. 
Digalloylresveratrol (DIG) was a gift from Univ.-Prof. Mag. Dr. Walter Jäger, Department 
of Clinical Pharmacy and Diagnostics, University of Vienna. 
All other chemicals and reagents used were commercially available and of highest purity. 
The following reagents and materials were purchased as described below: 
  
  
Ammoniumdihydrogenphosphate  VWR Merck, Vienna, Austria  
Cytidine-2-14C (56 Ci/mmol)  SIGMA, St. Louis, MO  
Sarcosine  SIGMA, St. Louis, MO  
TRIS/ EDTA buffer  SIGMA, St. Louis, MO  
Proteinase K  Roche, Vienna, Austria  
Sodium acetate  Life Technologies, Paisley, Scotland  
Phenol SIGMA, St. Louis, MO  
Chloroform  SIGMA, St. Louis, MO  
RNAse A  Amersham Pharmacia, Vienna,  
Phosphoric acid  VWR Merck, Vienna, Austria  
Acetonitril J.T. Baker 
Trichloroacetic acid  SIGMA, St. Louis, MO  
Freon  SIGMA, St. Louis, MO  
Tri-n-octylamine  SIGMA, St. Louis, MO  
Methylamine  SIGMA, St. Louis, MO  
Sodium periodate  SIGMA, St. Louis, MO  
L-Rhamnose  SIGMA, St. Louis, MO 
Deoxyadenosine triphosphate  SIGMA, St. Louis, MO  
Deoxycytosine triphosphate  SIGMA, St. Louis, MO  
Deoxythymidine triphosphate  SIGMA, St. Louis, MO  
Deoxyguanosine triphosphate  SIGMA, St. Louis, MO  
Adenosine triphosphate  SIGMA, St. Louis, MO  
Cytidine triphosphate  SIGMA, St. Louis, MO  
Guanosine triphosphate  SIGMA, St. Louis, MO  
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Thymidine triphosphate  SIGMA, St. Louis, MO  
Uridine triphosphate  SIGMA, St. Louis, MO  
Cellpack buffer  Mueller, Vienna, Austria  
Agarose Type VII  SIGMA, St. Louis, MO  
Trypan blue stain Life Technologies, Paisley, Scotland 
Ethanol  SIGMA, St. Louis, MO  
Hoechst dye 33258  SIGMA, St. Louis, MO  
Propidium iodide  SIGMA, St. Louis, MO  
 
3.2. Cell culture 
3.2.1. Devices 
 
Laminar air flow  Dipl. Ing. W. Ehret GmbH, 
Emmendingen, Germany 
Cytoperm2 incubator  Heraeus, Vienna, Austria  
Olympus IMT-2 Inverse  Olympus, Vienna, Austria  
CC-110 microcellcounter  SYSMEX, Kobe, Japan  
pocH- 100i Hepatologyanalyzer SYSMEX, Kobe, Japan 
Hettich Rotanta Centrifuge Hettich Zentrifugen, Tuttlingen, Germany 
Centrifuge 5415R Eppendorf 
Water Bath  Gesellschaft für Labortechnik mbH, 
Burgwedel,  
PH-Meter  Metrohm, Switzerland  
Mettler PJ 300/AT250 scales  Mettler, Vienna, Austria  
Magnetic Stirrer  Framo, Eisenbach, Germany  
Certoclav CV/CV-EL Autoclav  Certoclav, Vienna, Austria  
 
3.2.2. Cell culture media and supplements 
 
All media and supplements were obtained from Gibco Life Technologies, Ltd. (Paisley, 
Scotland, Great Britain):  
Dulbecco’s Modified Eagle Medium High Glucose  
RPMI 1640 Medium with L-Glutamine  
RPMI 1640 Medium with GLUTAMAX  
Fetal Bovine Serum, Heat Inactivated  
Penicillin/Streptomycin 10.000U/ml solution  
L-Glutamin 200mM solution  
Trypsin-EDTA 0.25% solution; Trypsin-EDTA 2.5% solution 
Sodium Pyruvate 100mM 
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3.2.3. Cell lines 
 
All tumor cell lines were purchased from ATCC (American Type Culture Collection, 
Manassas, VA, USA). The human HL-60 promyelocytic leukemia cells were grown in RPMI 
1640 medium with L-Glutamine supplemented with 10% heat inactivated fetal calf serum 
(FCS), 1% L-Glutamine and 1% Penicillin-streptomycin at 37°C in a humidified atmosphere 
containing 5% CO2 using a Heraeus cytoperm 2 incubator (Heraeus, Vienna, Austria). 
The AsPC-1 and BxPC-3 human pancreatic cancer cells were grown in RPMI 1640 Medium 
with GLUTAMAX supplemented with 10% heat inactivated fetal calf serum (FCS), 1% 
Sodium Pyruvat and 1% Penicillin-streptomycin at 37°C in a humidified atmosphere 
containing 5% CO2 using a Heraeus cytoperm 2 incubator (Heraeus, Vienna, Austria). The 
PA7C-1 human pancreatic cancer cells were grown in Dulbecco’s Modified Eagle Medium 
high Glucose supplemented with 10% heat inactivated fetal calf serum (FCS), 2% L-
Glutamine, 1% Penicillin-Streptomycin and 1% Sodium Pyruvate at 37°C in a humidified 
atmosphere. 
The attaching pancreatic cancer cells were grown in a monolayer culture using 25cm
2
 tissue 
culture flasks and were periodically detached from the flask surface using 0.25 or 2.5% 
trypsin ethylene–diamine tetraacetic acid (trypsin–EDTA) solution. 
 
Cell counts were determined using a microcellcounter CC-110 (SYSMEX, Kobe, Japan). 
Cells growing in the logarithmic phase of growth were used for all experiments described 
below. 
3.3. Growth inhibition assay 
 
HL-60 cells (0.1x10
6
 per ml) were seeded in 25cm
2
 Nunc tissue culture flasks and incubated 
with increasing concentrations of drugs at 37°C under cell culture conditions. Cell counts and 
IC50 values were determined after 24, 48, and 72 hours using the microcellcounter CC-110. 
Viability of cells was determined by trypan blue staining. Results were calculated as number 
of viable cells. All experiments were performed in triplicate. 
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3.3.1. Simultaneous growth inhibition assay 
 
HL-60 cells (0.1x10
6
 per ml) were simultaneously incubated with various concentrations of 
novel compounds and cytostatic drugs commonly used in cancer treatment (Ara-C or dFdC) 
for 72 hours. After that period, cells were counted using a microcellcounter CC-110. 
 
3.3.2. Sequential growth inhibition assay 
 
HL-60 cells (0.1x10
6
 per ml) were first incubated with different concentrations of novel 
compounds for 24 hours. Then the first compound was washed out and cells were further 
exposed to various concentrations of commonly used cytostatic drugs (Ara-C or dFdC) for 
another 48 hours. After that period, cells were counted using a microcellcounter CC-110. 
 
3.4. Clonogenic assay 
 
Attaching pancreatic tumor cells (1x10
3
 perwell) were seeded in 24-well plates and allowed to 
attach overnight at 37˚C in a humidified 5% CO2 atmosphere. After 24 hours, the medium 
was removed and replaced by a fresh medium containing the designated concentration of 
drugs. The plates were then incubated for 7 days. Subsequently, the medium was carefully 
removed from the wells and the plates were stained with 0.5% crystal violet solution for 5 
min. Colonies of >50 cells were counted using an inverted microscope at 40-fold 
magnification. All experiments were performed in triplicate and repeated three times. 
 
3.4.1. Simultaneous clonogenic assay  
 
Pancreatic cells (1x10
3
 per well) were plated in 24-well plates and allowed to attach overnight 
at 37˚C in a humidified 5% CO2 atmosphere. After 24 hours, the medium was removed and 
replaced by a fresh medium containing the designated concentrations of novel compounds and 
cytostatic drugs commonly used in cancer treatment (Ara-C or dFdC). The plates were then 
incubated for 7 days. Further procedure as described above. 
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3.4.2. Sequential clonogenic assay 
 
Pancreatic cells (1x10
3
 per well) were plated in 24-well plates and allowed to attach overnight 
at 37˚C in a humidified 5% CO2 atmosphere. After 24 hours, the medium was removed and 
replaced by a fresh medium containing the designated concentration of the novel compound 
and incubated for another 24 hours. Then the medium was removed again and cells were 
further exposed to various concentrations of a commonly used cytostatic drug. The plates 
were then incubated for another 6 days. Further procedure as described above. 
 
3.5. Hoechst dye 33258 and propidium iodide double staining 
 
Cells (0.4x10
6
 per ml) were seeded in 25cm
2
 Nunc tissue culture flasks and exposed to 
increasing concentrations of drugs for 24 or 48 hours. Hoechst 33258 (HO, Sigma, St. Louis, 
MO, USA) and propidium iodide (PI, Sigma, St. Louis, MO, USA) were added directly to the 
cells to final concentrations of 5µg/ml and 2µg/ml, respectively. After 60 min of incubation at 
37°C, cells were examined on a Leica DMR XA fluorescence microscope (Leica, Wetzlar, 
Germany) equipped with appropriate filters for Hoechst 33258 and PI. The Hoechst dye stains 
the nuclei of all cells and therefore allows to monitor nuclear changes associated with 
apoptosis, such as chromatin condensation and nuclear fragmentation. PI, on the other hand, is 
excluded from viable and early apoptotic cells; consequently, PI uptake indicates loss of 
membrane integrity characteristic of necrotic and late apoptotic cells. Therefore, this method 
allows to distinguish between early apoptosis, late apoptosis, and necrosis. Cells were 
photographed with a COHU high performance CCD camera (COHU Inc., San Diego, CA, 
USA) using Leica Q-fish software and were counted under a microscope and the number of 
apoptotic cells was given as percentage value. 
 
3.6. Cell cycle distribution analysis 
 
Cells (0.4x10
6
 per ml) were seeded in 25cm
2
 Nunc tissue culture flasks and incubated with 
increasing concentrations of drugs at 37°C under cell culture conditions. After 24 hours, cells 
were harvested and suspended in 5ml cold PBS, centrifuged, resuspended and fixed in 3ml 
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cold ethanol (70%) for 30 min at 4°C. After two washing steps in cold PBS, RNAse A and 
propidium iodide were added to a final concentration of 50µg/ml each and incubated at 4°C 
for 60 min before measurement. Cells were analyzed on a FACSCalibur flow cytometer (BD 
Biosciences, San Jose, CA, USA) and cell cycle distribution was calculated with ModFit LT 
software (Verity Software House, Topsham, ME, USA). 
 
3.7. Determination of deoxyribonucleoside triphosphates (d7TPs) 
 
Logarithmically growing HL-60 or AsPC-1 cells were incubated with increasing 
concentrations of drugs for 24 hours. Afterwards, 5x10
7
 cells were separated for the extraction 
of dNTPs according to a method established Garrett et al. Cells were centrifuged at 1800 rpm 
for 5 min and then resuspended in 100µl phosphate-buffered saline. In this suspension, cells 
were lysed by addition of 10µl of trichloroacetic acid and the mixture was vortexed for 1 
minute. The lysate was rested on ice for 30 min and then the protein was separated by 
centrifugation at 15000 rpm for 10 min in an Eppendorf microcentrifuge. The supernatant was 
removed and neutralized by adding 1.1 vol of Freon containing 0.5 M tri-n-octylamin. 
Aliquots of 100µl were periodated by adding 30µl of 4M methylamine solution and 10µl 
sodium periodate solution (concentration: 100g/l). After incubation at 37°C for 30 min, the 
reaction was stopped by adding 5µl of 1M rhamnose solution. The extracted dNTPs were 
measured using a Merck „La Chrom” HPLC system equipped with L-7200 autosampler, L-
7100 pump, L-7400 UV detector, and D-7000 interface. Samples were eluted with a 3.2M 
ammonium phosphate buffer, pH 3.6 (pH adjusted by addition of 0.32mol/l H3PO4), 
containing 20mM acetonitrile using a 4.6x250mm Partisil 10 SAX analytical column 
(Whatman Ltd., Kent, UK). Separation was performed at constant ambient temperature with a 
flow rate of 2ml/min. The concentration of dNTPs was calculated as percent of total area 
under the curve for each sample. 
 
 
 
 
33 
 
3.7.1. Ara-CTP determination 
 
Ara-CTP determination was performed according to the same method without the periodation 
step and a 3.2M ammonium phosphate buffer, pH 3.3. 
 
3.8. Incorporation of 14C-labelled cytidine into D7A  
 
To analyze the effect of drug incubation on the activity of DNA synthesis, an assay was 
performed as described previously (Szekeres et al, 1994). Logarithmically growing HL-60 or 
AsPC-1 cells (0.3x10
6
 cells per ml) were incubated with various concentrations of drugs for 24 
hours. After the incubation period, cells were counted and pulsed with 
14
C-cytidine (0.3125µCi, 
5nM) for 30 min at 37°C. Then cells were collected by centrifugation and washed with PBS. Total 
DNA was extracted from 5x10
6
 cells by phenol-chloroform-isoamyl alcohol extraction and 
specific radioactivity of the samples was determined using a Wallac 1414 liquid scintillation 
counter (PerkinElmer, Boston, MA). 
 
3.9. MTT chemosensitivity assay 
 
AsPC-1 or HL-60 cells (5x10
3
 per well) were seeded in 96-well microtiter plates in 
supplemented RPMI 1640 medium. AsPC-1 cells were allowed to attach overnight. Cells 
were then incubated with various concentrations of ABNM-13 for 96 hours at 37°C under cell 
culture conditions. After that period, the reduction of the yellow tetrazolium compound 3-
(4,5-dimethylthiazo-2-yl)-2,5-diphenyltetrazoliumbromide (MTT) by the mitochondrial 
dehydrogenases of viable cells to a purple formazan product was determined using an assay 
kit from Promega1 according to the supplier’s manual. The change in absorbance at 550nm 
was tracked on a Wallac 1420 Victor 2 multilabel plate reader (PerkinElmer Life and 
Analytical Sciences). Drug effect was quantified as the percentage of control absorbance of 
reduced dye at this wavelength. 
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3.10. DPPH radical scavenging activity assay 
 
The radical scavenging activity of the tested compounds was determined using the free radical 
2,2-diphenyl-1-picrylhydrazyl (DPPH). In its radical form, DPPH absorbs at 515nm but upon 
reduction by an antioxidant or radical species, its absorption decreases. The reaction was 
started by the addition of 10µl of the compound (5–100µM final concentration) to 3.0ml of 
0.1mM DPPH in methanol. The bleaching of DPPH was followed using an HP 8453 diode 
array spectrometer equipped with a magnetically stirred quartz cell. Absorbance was recorded 
for up to 10 min, although steady states of reaction were reached in most cases within 3 min. 
The reference cuvette contained up to 0.1mM DPPH in 3.0ml of methanol. The DPPH radical 
scavenging activity obtained for each compound was compared with that of ascorbic acid and 
α-Tocopherol. 
 
3.11. Western blotting 
 
HL-60 cells or AsPC-1 cells were seeded in 25cm
2
 tissue culture flasks or 100mm Tissue 
Culture Dishes, respectively, at a concentration of 2×10
6
 per ml medium and incubated with a 
specific concentration of drug (IC50 value) for 0.5, 2, 4, 8, and 24 hours. 
After incubation cells were harvested, washed twice with ice-cold PBS (pH 7.2) and lysed in a 
buffer containing 150mM NaCl, 50mM Tris-buffered saline (Tris pH 8.0), 1% Triton X-100, 
1mM phenylmethylsulfonylfluoride (PMSF) and protease inhibitor cocktail (PIC; from a 100x 
stock). The lysate was centrifuged at 12000 rpm for 20 min at 4°C, and the supernatant was 
stored at -20°C until further analysis. 
 
Equal amounts of lysate (protein samples) were loaded onto polyacrylamide gels. Proteins 
were electrophoresed (PAGE) at 120 volt (50mA) for approximately 1 hour and then 
electroblotted onto PVDF membranes (Hybond P, Amersham, Buckinghamshire, UK) at 95 V 
and 4ºC for 80 min. 
Equal sample loading was controlled by staining membranes with Ponceau S. After washing 
with PBS/Tween-20 (PBS/T) pH 7.2 or Tris/Tween-20 (TBS/T) pH 7.6, membranes were 
blocked for 60 min in blocking solution (5% non-fat dry milk in PBS containing 0.5% Tween-
20 or in TBS containing 0.1% Tween-20). 
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Then membranes were incubated with the first antibody (in blocking solution, dilution 1:500 
to 1:1000) by gently rocking at 4°C, overnight. Subsequently, the membranes were washed 
with PBS or TBS and further incubated with the second antibody (peroxidase-conjugated goat 
anti-rabbit IgG, anti-mouse IgG, or donkey anti-goat IgG dilution 1:2000 to 1:5000 in PBS/T 
or TBS/T) at room temperature for 60 min. 
Membranes were washed with PBS/Tween-20 (PBS/T) pH 7.2 or Tris/Tween-20 (TBS/T) pH 
7.6. Chemoluminescence was developed by the ECL detection kit (Amersham, 
Buckinghamshire, UK) and then membranes were exposed to Amersham Hyperfilms. 
 
3.11.1. Antibodies 
chk1 #2345, polyclonal (Cell Signaling) 
chk2 #2662, polyclonal (Cell Signaling) 
pchk1 #2344, polyclonal (Cell Signaling) 
pchk2 #2661, polyclonal (Cell Signaling) 
cdc25A #sc-7389, monoclonal (Santa Cruz) 
cdc25B #sc- 326, polyclonal (Santa Cruz) 
cdc25C #sc- 327, polyclonal (Santa Cruz) 
pcdc25A (Ser75) #ab47279, polyclonal (Abcam) 
pcdc25A (Ser177) #AP3046a, polyclonal Abgent) 
cdc2 #sc-54, monoclonal (Santa Cruz) 
pcdc2 #4539, monoclonal (Cell Signaling) 
R1 #sc-11733, polyclonal (Santa Cruz) 
R2 #sc-10848, polyclonal (Santa Cruz)  
P53R2 #sc-10840, polyclonal (Santa Cruz) 
anti-H2AX #DR1017, polyclonal (Calbiochem) 
p-ATM #4526, monoclonal (Cell Signaling) 
p-ATR #2853, polyclonal (Cell Signaling) 
Cleaved Caspase-3 #9661, polyclonal (Cell Signaling) 
Anti-ß-Actin clone AC-15, mouse ascites fluid, No. 
A5441 (Sigma) 
Phospho-p44/42 MAPK (Erk1/2) #9106, monoclonal (Cell Signaling) 
p44/42 MAPK (Erk1/2) #4695, monoclonal (Cell Signaling) 
anti-goat IgG antibody #10209, (Santa Cruz) 
anti-mouse IgG/ HRP #P0260, polyclonal (Dako) 
Anti-rabbit IgG/ HRP #P0217, polyclonal (Dako) 
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3.12. Statistical calculations 
 
Dose-response curves were calculated using the Prism 5.01 software package (GraphPad, San 
Diego, CA, USA) and statistical significance was determined by unpaired t-test. The 
calculations of dose response curves and combination effects were performed using the 
"Calcusyn" software designed by Chou and Talalay (Biosoft, Ferguson, MO). 
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4. Results 
4.1. AB7M-13 
4.1.1. Effect of AB7M 1-13 on the growth of HL-60 cells 
 
HL-60 cells (0.1x10
6
 per ml) were seeded in 25cm
2
 Nunc tissue culture flasks and incubated 
with increasing concentrations of ABNM 1-13. After 72 hours, the cell number of viable 
leukemia cells was determined. ABNM-4, ABNM-8, ABNM-9, ABNM-12, and ABNM-13 
inhibited the growth of HL-60 cells with IC50 values (IC50 = 50% growth inhibition of tumor 
cells) of 95, 67, 60, 62, and 11µM, respectively. The IC50 values of all other compounds 
remained beyond 100µM (figure 7). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Structural and biological activity of AB7M 1-13 in HL-60 cells 
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All further investigations were established with the most efficacious compound, ABNM-13. 
 
4.1.2. Effect of AB7M-13 on the growth of HL-60 cells 
 
HL-60 cells were seeded at a concentration of 0.1x10
6
 per ml and incubated with increasing 
concentrations of ABNM-13. After 24, 48 and 72 hours, the cell number of viable leukemia 
cells was determined. ABNM-13 inhibited the growth of HL-60 cells with IC50 values (IC50 = 
50% growth inhibition of tumor cells) of 15 after 48 hours and 11µM after 72 hours, 
respectively (figure 8). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.1.2.1. Synergistic combination effects of AB7M-13 and Ara-C in HL-60 cells 
 
To investigate the effect of ABNM-13 in combination with Ara-C, HL-60 cells were seeded at 
a concentration of 0.1x10
6
 per ml and simultaneously or sequentially incubated with 
increasing concentrations of drugs (ABNM-13 first for 24 hours and then Ara-C for 48 hours 
as described in the methods section). Three out of twelve drug combinations caused 
synergism when ABNM-13 and Ara-C were applied simultaneously (table 1). Moreover, all 
twelve combinations yielded highly synergistic effects when applied sequentially (cells were 
first incubated with 2.5, 5, 7.5, and 10µM ABNM-13 followed by the addition of 5, 10, and 
20nM Ara-C, respectively) (table 2). 
Figure 8: Growth inhibition of HL-60 cells after incubation with AB7M-13 
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Table 1: Synergistic combination effects of ABNM-13 and Ara-C in HL-60 cells employing a 
simultaneous growth inhibition assay 
Compound Concentration 
(µM/nM) 
Cell number ± SD 
(% of control) 
Predicted value* Combination 
Index** 
     
ABNM-13 (A) 2.5 96.4 ± 3.50   
(µM) 5.0 74.3 ± 0.64   
 7.5 68.1 ± 0.48   
 10.0 53.2 ± 2.23   
     
Ara-C (B) 10 62.0 ± 1.12   
(nM) 15 50.7 ± 0.96   
 20 40.8 ± 0.32   
     
ABNM-13 2.5    
+ Ara-C 10 55.2 ± 0.96 59.8 1.064 
     
ABNM-13 2.5    
+ Ara-C 15 39.8 ± 0.48 48.8 0.924 
     
ABNM-13 2.5    
+ Ara-C 20 33.8 ± 0.64 39.3 0.961 
     
ABNM-13 5    
+ Ara-C 10 40.4 ± 1.12 46.1 0.910 
     
ABNM-13 5    
+ Ara-C 15 31.9 ± 1.16 37.7 0.899*** 
     
ABNM-13 5    
+ Ara-C 20 30.3 ± 2.70 30.3 1.027 
     
ABNM-13 7.5    
+ Ara-C 10 3.1 ± 0.48 42.3 1.005 
     
ABNM-13 7.5    
+ Ara-C 15 28.8 ± 1.27 34.5 0.824*** 
     
ABNM-13 7.5    
+ Ara-C 20 26.4 ± 0.00 27.8 1.057 
     
ABNM-13 10    
+ Ara-C 10 30.3 ± 0.16 33.0 1.031 
     
ABNM-13 10    
+ Ara-C 15 23.9 ± 0.32 26.9 0.858*** 
     
ABNM-13 10    
+ Ara-C 20 22.6 ± 0.80 21.7 1.074 
     
 
Cells were simultaneously incubated with (1) ABNM-13 for 24h and (2) Ara-C for 48h, and then the cell 
number was determined. Data are means of two determinations ± standard deviations (SD). 
 
* Predicted Value: (%A x %B) / 100 
** Combination indices according to the equation of Chou and Talalay (Chou and Talalay, 1981) 
*** Synergistic combination effect 
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Table 2: Synergistic combination effects of ABNM-13 and Ara-C in HL-60 cells employing a 
sequential growth inhibition assay 
Compound Concentration 
(µM/nM) 
Cell number ± SD 
(% of control) 
Predicted value* Combination 
Index** 
     
ABNM-13 (A) 2.5 88.7 ± 0.78   
(µM) 5.0 61.8 ± 0.16   
 7.5 50.9 ± 0.78   
 10.0 32.6 ± 0.31   
     
Ara-C (B) 10 72.4 ± 0.94   
(nM) 15 71.8 ± 3.61   
 20 59.3 ± 3.45   
     
ABNM-13 2.5    
+ Ara-C 10 49.2 ± 4.55 64.2 0.607*** 
     
ABNM-13 2.5    
+ Ara-C 15 25.2 ± 4.87 63.7 0.305*** 
     
ABNM-13 2.5    
+ Ara-C 20 39.8 ± 2.35 52.6 0.607*** 
     
ABNM-13 5    
+ Ara-C 10 15.5 ± 7.85 44.7 0.329*** 
     
ABNM-13 5    
+ Ara-C 15 20.0 ± 5.65 44.4 0.418*** 
     
ABNM-13 5    
+ Ara-C 20 32.1 ± 1.10 36.6 0.692*** 
     
ABNM-13 7.5    
+ Ara-C 10 17.3 ± 5.02 36.9 0.514*** 
     
ABNM-13 7.5    
+ Ara-C 15 26.4 ± 0.00 36.6 0.740*** 
     
ABNM-13 7.5    
+ Ara-C 20 23.2 ± 1.41 30.2 0.695*** 
     
ABNM-13 10    
+ Ara-C 10 17.2 ± 2.04 23.6 0.670*** 
     
ABNM-13 10    
+ Ara-C 15 16.8 ± 1.73 23.4 0.676*** 
     
ABNM-13 10    
+ Ara-C 20 17.9 ± 2.67 19.3 0.727*** 
     
 
Cells were sequentially incubated with (1) ABNM-13 for 24h and (2) Ara-C for 48h, and then the cell 
number was determined. Data are means of two determinations ± standard deviations (SD). 
 
* Predicted Value: (%A x %B) / 100 
** Combination indices according to the equation of Chou and Talalay (Chou and Talalay, 1981) 
*** Synergistic combination effect 
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4.1.3. Inhibition of incorporation of 14C-cytidine into D7A of HL-60 cells after 
treatment with AB7M-13 and/or Ara-C 
 
The RR in situ activity was measured in HL-60 cells after incubation with increasing 
concentrations of ABNM-13. Exposure to 10, 20, and 40µM ABNM-13 for 24 hours 
significantly decreased 
14
C-cytidine incorporation into nascent DNA to 52%, 17%, and 4%, 
respectively (figure 9a).  
To analyze the immediacy of RR inhibition, HL-60 cells were exposed to 15 nM Ara-C, 
15µM ABNM-13, and the simultaneous combination of both compounds for only 30 min. 
Even this short incubation period reduced the incorporation of 
14
Cytidine to 93%, 27%, and 
4% of controls, respectively (figure 9b). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 9a: Inhibition of 
14
C-incorporation into D7A of HL-60 cells after treatment with AB7M-13 for 
24 hours 
Figure 9b: Inhibition of 
14
C-incorporation into D7A of HL-60 cells after treatment with 
AB7M-13 and/or Ara-C for 30 min 
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4.1.4. Alterations of d7TP pool sizes in HL-60 cells after treatment with AB7M-
13 for 24 hours 
 
Constitutive RR activity maintains balanced dNTP pools, whereas RR inhibition tilts this 
balance. In line with the inhibition of RR in situ activity, ABNM-13 treatment caused also an 
imbalance of dNTPs in HL-60 cells after 24 hours, which was determined by HPLC analysis. 
Incubation of cells with 40µM ABNM-13 resulted in a significant depletion of intracellular 
dGTP pools to 36%. Treatment with 10, 20, and 40µM ABNM-13 significantly increased 
dTTP pools to 134%, 200%, and 237% of control values, respectively. Regarding dCTP and 
dATP pools, treatment with ABNM-13 led to insignificant changes (figure 10). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10: Concentration of d7TP pools in HL-60 cells after treatment with AB7M-13 for 24 
hours 
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4.1.5. Expression of RR subunits R1, R2, and p53R2 after treatment with 
AB7M-13 and/or Ara-C 
 
To monitor the effect of RR inhibitors on the expression of RR subunits, HL-60 cells were 
incubated with 15nM Ara-C and/or 15µM ABNM-13 for 0.5, 2, 4, 8, and 24 hours and 
subjected to western blot analysis. The protein level of the constitutively expressed R1 
subunit remained unchanged during the whole time course, whereas the levels of S-phase 
specific R2 and p53R2 subunits were elevated after 8 and 24 hours of incubation (figure 11). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.1.6. Cell cycle distribution in HL-60 cells after treatment with AB7M-13 
and/or Ara-C 
 
HL-60 cells were simultaneously incubated with 15µM ABNM-13 and/or 15nM Ara-C for 24 
hours. Treatment of HL-60 cells with 15µM ABNM-13 caused cell cycle arrest in S-phase, 
increasing this cell population from 34% to 62%, whereas G0-G1 phase cells decreased from 
46% to 21%. 15nM Ara-C likewise caused an accumulation of 69% HL-60 cells in S-phase 
and a concomitant decrease of G0-G1 cells to 12%. Simultaneous incubation of HL-60 cells 
with 15µM ABNM-13 and 15nM Ara-C led to an even more pronounced growth arrest in the 
Figure 11: Expression of RR subunits in HL-60 cells after treatment with AB7M-13 and/or Ara-C 
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S-phase, increasing this cell population from 34% to 94% while decreasing cells in the G0-G1 
phase from 46% to 6% (figures 12a-c). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12c: HL-60 cell cycle distribution after simultaneous incubation with AB7M-13 and Ara-C 
 
 
Figure 12a: HL-60 cell cycle distribution after incubation with AB7M-13 
Figure 12b: HL-60 cell cycle distribution after incubation with Ara-C 
45 
 
 
4.1.7. Expression of checkpoint and cell cycle regulating proteins after treatment 
with AB7M-13 and/or Ara-C 
 
To investigate whether S-phase inhibition caused activation of cell cycle checkpoint kinases, 
HL-60 cells were simultaneously treated with 15 nM Ara-C and/or 15µM ABNM-13 for 0.5, 
2, 4, 8, and 24 hours and subjected to western blot analysis. Chk1 was phosphorylated at the 
activating Ser317 site within 30 min (Ara-C), 2 hours (ABNM-13), and 2 hours (Ara-
C/ABNM-13). Chk2 was phosphorylated at the activating Thr68 site within 24 hours (Ara-C), 
30 min (ABNM-13), and 30 min (ABNM-13/Ara-C). Chk1 and Chk2 protein levels remained 
unchanged (figure 13a). In addition, ABNM-13 caused phosphorylation at Ser75 and Ser177 
of the dual-specificity phosphatase Cdc25A, which are target sites of Chk1 and Chk2, 
respectively, resulting in its downregulation after 8 and 24 hours. On the other hand, ABNM-
13 upregulated Cdc25B protein levels after 24 hours (Ara-C after 8 and 24 hours), resulting in 
the dephosphorylation of Tyr15 of Cdk1 after 24 hours, which is indicative for its activation. 
Ara-C treatment did not cause dephosphorylation of Cdk1. Cdc25C levels remained 
unchanged throughout the time course (figure 13b). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13a: Expression of checkpoint and cell cycle regulators upon treatment with AB7M-13 
and/or Ara-C 
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Figure 13b: Expression of cell cycle regulators upon treatment with AB7M-13 and/or Ara-C 
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4.1.8. Induction of apoptosis in HL-60 cells by AB7M-13 and/or Ara-C 
 
HL-60 cells were exposed to 12.5, 15, 17.5, and 20µM ABNM-13 for 48 hours and double 
stained with Hoechst 33258 and propidium iodide to analyze whether apoptotic cell death was 
induced. The nuclear morphology of 22% HL-60 cells showed early as well as late apoptosis 
stages upon treatment with 15µM ABNM-13 (figure 14a), indicating that cell cycle inhibition 
rather than induction of apoptosis seems to be the primary antineoplastic effect of ABNM-13. 
Incubation with 15nM Ara-C or the combination of 15µM ABNM-13 and 15nM Ara-C for 48 
hours resulted in 10 and 28% apoptotic cells, respectively (figure 14b). 
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Figure 14a: Induction of apoptosis in HL-60 cells after treatment with AB7M-13 
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 Figure 14b: Induction of apoptosis in HL-60 cells after treatment with 15µM AB7M-13 and/or 
15nM Ara-C 
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The induction of apoptosis was further substantiated by the cleavage and therefore activation 
of caspase-3 after 8 and 24 hours of treatment with 15µM ABNM-13 or the combination of 
15µM ABNM-13 and 15 nM Ara-C, which in turn led to increased protein levels of γH2AX 
after 24 hours. In contrast, 15 nM Ara-C induced activated caspase-3 and γH2AX levels only 
marginally (figure 14c). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14c: Expression levels of cleaved caspase-3 and γH2AX after incubation 
with AB7M-13 and/or Ara-C 
 
          
Early apoptosis 
(Hoechst stain) 
Untreated control 
Late apoptosis (Propidium iodide stain) 
Figure 14d: Examples of the cellular morphology of HL-60 cell after incubation with 
AB7M-13 for 48 hours. Cells were double stained with Hoechst dye 33258 plus propidium 
iodide 
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4.1.9. MTT chemosensitivity assay 
 
HL-60 cells (5×10
3
 per well) were seeded in 96-well microtiter plates and exposed to 
increasing concentrations of ABNM-13 as described in the methods section. After 96 hours of 
incubation, ABNM-13 reduced the absorbance (viability) of HL-60 cells with an IC50 value of 
9 ± 1.7µM (figure 15). 
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Figure 15: MTT chemosensitivity assay of HL-60 cells after treatment with AB7M-13 
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4.2. DIG 
 
4.2.1. Clonogenic assays in AsPC-1, BxPC-3, PA7C-1 cells – effects of DIG, 
dFdC, GA and RV 
 
Logarithmically growing pancreatic cells were incubated with various concentrations of drugs 
for 7 days. Cell colonies were counted after 7 days of incubation as explained in the methods 
section. DIG inhibited the growth of AsPC-1 cell with an IC50 value of 21.5µM, BxPC-3 cells 
with an IC50 value of 8.5µM and PANC-1 cells with an IC50 value of 9.5µM (figures 16a-c). 
All further inhibitory effects are showed in table 2. 
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Figures 16a-c: Growth inhibition of AsPC-1 (a), BxPC-3 (b), PA7C-1 (c) cells after treatment with 
various concentrations of DIG 
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4.2.1.1. Combination effects of DIG and dFdC on the growth of AsPC-1 cells  
 
To investigate the effect of DIG in combination with dFdC, AsPC-1 cells were seeded at a 
concentration of 1×10
3 
cells/well and sequentially incubated with increasing concentrations of 
drugs. Cells were first incubated with 25, 30, 35µM ABNM-13 for 24 hours and then with 
2.5, 3, 3.5nM dFdC for 7 days as described in section 2. However, none of the 12 
concentrations yielded any synergistic effects (data not shown). 
 
Table 2: Comparison of the effect of DIG, dFdC, GA and RV on human pancreatic cancer cells. 
Compound MW AsPC-1 BxPC-3 PA7C-1 
     
dFdC 263.20 3.25nM 1.85nM 1.5nM 
DIG 532.47 21.5µM 8.5µM 9.5µM 
GA 170.12 21.0µM 41.0µM 8.5µM 
RV 228.25 18.0µM 13.3µM 7.5µM 
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4.2.2. Antioxidant activity of DIG, RV, GA 
 
The in vitro free radical-scavenging activity of DIG, RV, GA and equimolar combinations of 
RV and GA was determined employing a DPPH-assay. After incubation for 10 min DIG, RV, 
and GA inhibited 50% of DPPH activity with IC50 values of 1.83, 98.3, and 3.12µM, 
respectively (figures 17a-d). The combination of RV and GA inhibited 50% of DPPH activity 
at 4.82µM. Tocopherol and ascorbic acid were used as reference compounds resulting in IC50 
values of 6.98µM and 9.63µM, respectively. 
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Figure 17: Antioxidant activity of DIG (a), GA (b), RV (c)and RV: GA (1:2) (d) after incubation for 10 min 
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4.2.3. Inhibition of incorporation of 14C-cytidine into D7A of AsPC-1, BxPC-3, 
PA7C-1 cells after treatment with various concentrations of DIG 
 
The RR in situ activity was measured in AsPC-1, BxPC-3, PANC-1 cells after incubation 
with various increasing concentrations of DIG. AsPC-1 was exposed to 20, 25, 30, and 35µM 
DIG. After 24 hours, the incorporation of 
14
C-cytidine was significantly reduced to 7%, 5%, 
5%, and 4%. BxPC-3 and PANC-1 were exposed to 5, 10, 15 and 20µM DIG for 24 hours. 
The incorporation of 
14
C-cytidine into nascent DNA significantly decreased in both cancer 
cell lines (BxPC-3 to 2%, 0%, 1%, and 1% and PANC-1 to 3%, 0%, 0%, and 1%) (figures 
18a-c). 
 
 
 
 
 
 
 
 
 
 
 
 
4.2.4. Cell cycle distribution in AsPC-1, BxPC-3, PA7C-1 cells after treatment 
with DIG 
 
Pancreatic cancer cell lines were incubated with different concentrations of DIG for 24 hours. 
Treatment of AsPC-1 cells with 30µM DIG caused an accumulation of cells in S phase, 
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Figures 18a-c: Inhibition of 14C-Incorporation into D7A of AsPC-1 (a), BxPC-3 (b), PA7C-1 (c) cells 
after treatment with DIG for 24 hours. 
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increasing this cell population from 13% to 22%, whereas G2-M phase cells decreased from 
32% to 16%. Growth arrest in BxPC-3 cells after exposure to 12.5µM DIG occurred mainly 
in the G2-M phase, increasing the cell population from 18% to 12.5% while depleting cells in 
the S-phase from 38% to 26%. In PANC-1 cells, a significant decrease or increase of cells in 
specific cell cycle phases was not observed at any concentration applied (figure 19a-c). 
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Figure 19a: AsPC-1 cell cycle distribution after incubation with DIG 
Figure 19b: BxPC-3 cell cycle distribution after incubation with DIG 
Figure 19c: PA7C-1 cell cycle distribution after incubation with DIG 
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4.2.5. Induction of apoptosis in AsPC-1, BxPC-3, PA7C-1 cells by DIG 
 
Pancreatic cancer cells were exposed to increasing concentrations of DIG for 72 hours and 
double stained with Hoechst 33258 and propidium iodide to analyze whether apoptotic cell 
death was induced. Neither AsPC-1 nor PANC-1 cells showed any significant apoptosis 
stages. 8.5% of AsPC-1 cells showed early as well as late apoptosis stages upon treatment 
with 30µM DIG (figure 20a); upon treatment with 7.5 and 15µM DIG approximately 6.5% of 
PANC-1 cells showed the same apoptotic and necrotic effects (figure 20b). For technical 
reasons apoptosis induction could not be evaluated in BxPC-3 cells. In line with these 
findings, western blot analysis after treatment of AsPC-1 cells with 40µM DIG showed that 
caspase 3 protein level remained unchanged. 
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Figure 20a: Induction of apoptosis in AsPC-1 cells after treatment with DIG 
Figure 20b: Induction of apoptosis in PA7C-1 cells after treatment with DIG 
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4.2.6. Alterations of d7TP pool sizes in AsPC-1 cells after treatment with DIG 
 
AsPC-1 cells were incubated with 20, 30, 40µM DIG for 24 hours. Then the dNTP pool sizes 
were determined using the HPLC method described in the methods section. Treatment with 
DIG caused an imbalance of dNTP pool sizes in AsPC-1 cells. A depletion of dATP 
concentrations to 31% of control values could be observed after treatment with DIG. While 
dCTP remained unaltered, dTTP concentrations increased up to 130% of control values after 
incubation of cells with DIG. All dGTP pools remained beyond the detectability of the 
method (figure 21). 
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Figure 21: Concentration of d7TP pools in AsPC-1 cells after treatment with DIG 
for 24 hours 
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4.2.7. Expression of checkpoint and cell cycle regulating proteins after treatment 
of AsPC-1 cells with DIG 
 
To investigate the expression of cell cycle regulators, AsPC-1 cells were treated with 40µM 
DIG for 0.5, 2, 4, 8, and 24 hours and examined by western blot analysis. Chk2 was only 
marginally phosphorylated at the activating Thr68 site within 24 hours. Chk2 levels remained 
unchanged. Furthermore, DIG caused phosphorylation at Ser177 of phosphatase Cdc25A, 
which is a target of Chk2, resulting in a transient induction of Cdc25A. In addition, treatment 
with DIG resulted in phosphorylation at Ser1981 of ATM kinase, which requires DNA 
damage and causes phosphorylation of Chk2 (figure 22). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 22: Expression of cell cycle regulators after treatment 
of AsPC-1 cells with 40µM DIG 
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4.2.8. Expression of mitogen activated protein kinases after treatment of AsPC-1 
with DIG 
 
Western blot analysis demonstrated the effect of 40µM DIG on mitogen-activated proteins in 
AsPC-1 cells after treatment for 0.5, 2, 4, 8, and 24 hours. Phosphorylation of Erk1/2 was 
reduced within 4 hours. However, DIG showed a marginal induction effect on the p38 
pathway. In addition, treatment with DIG resulted in phosphorylation at Ser473 of Akt kinase 
within 2 hours (figure 23). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 23: Western blot analysis demonstrating the effect of 40µM DIG 
in AsPC-1 cells on mitogen-activated protein kinase signaling pathways 
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5. Discussion 
5.1. AB7M-13 
 
A panel of 13 novel compounds (ABNM 1-13) was synthesized by a 3D molecular space 
modeling technique aiming at the inhibition of RR activity. The enzyme represents the rate-
limiting factor of DNA synthesis. Growth inhibition assays in human HL-60 promyelocytic 
leukemia cells with all newly synthesized agents revealed that ABNM-13 was the most active 
compound. 
Subsequently, ABNM-13 was shown to strongly inhibit the in situ RR activity despite low 
concentrations and a short incubation time. Furthermore, this newly designed agent caused 
alterations of the dNTP pools thereby causing a significant depletion of the dGTP pools while 
elevating the dTTP pools. Due to that imbalance de novo DNA synthesis is disturbed and cell 
proliferation blocked. In line with this, ABNM-13 treatment also caused cell cycle 
perturbations, induction of apoptosis, and growth arrest of HL-60 cells. 
ABNM-13 led to a strong S-phase arrest, which is correlative with important RR properties: 
The enzyme forms the rate limiting factor for S-phase transit and inhibition of RR thus leads 
to inhibition of cells in S-phase (Chimploy et al, 2009). 
The expression level of the R1 subunit protein of RR remained unchanged while the S-phase 
specific R2 and p53R2 subunits were elevated although HL-60 cells are normally p53 
deficient. This finding suggests the assumption that cells try to rebalance the dNTP 
production by a compensatory up-regulation of p53R2 and is in line with recent observations 
made by Yanamoto et al showing that the basal level of p53R2 protein is expressed 
independent of the cellular p53 status (Yanamoto et al, 2005). Furthermore, Zhang et al 
demonstrated that up-regulation of R2 correlates with DNA damage and causes up-regulation 
and activation of Chk1 (Zhang et al, 2009). 
Cell cycle checkpoint kinases are activated by DNA damage, imbalance of dNTP pools or by 
incomplete DNA replication. That difficult control system prevents DNA synthesis, interrupts 
further cell cycle progression and provides time for either reconstitution of dNTP balance or 
DNA repair before the damage gets passed on to daughter cells (Kastan and Bartek, 2004; 
Shiloh, 2003; Bartek and Lukas, 2003). 
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Before replicating cells undergo mitosis, three major cell cycle checkpoint kinases have to be 
passed. Up-regulation and activation of these checkpoint proteins is controlled by specific key 
regulator proteins, ATR and ATM kinases. ATR activates downstream effector kinase Chk1 
while ATM activates effector kinase Chk2 by phosphorylation (Bartek and Lukas, 2003; 
Abraham, 2001). Activation of Chk1 or Chk2 results in phosphorylation of Cdc25A 
phosphatase at Ser75 and Ser177, respectively. Phosphorylation of Cdc25A oncogene tags the 
protein for proteasomal degradation. The phosphastase is required for maintaining cell cycle 
transit. Treatment with 15µM ABNM-13 activated both effector kinases Chk1 and Chk2, 
respectively. Chk2 protein was phosphoylated within 30 min. 
Phosphatases Cdc25B and Cdc25C induce cells entering mitosis by activating Cdk1/ cyclin B 
(Donzelli and Draetta, 2003), whereas Cdc25B is indicated to be the initial phosphatase to 
activate Cdk1/ cyclin B protein (Nishijima et al, 1997). Activation causes phosphorylation 
and activation of Cdc25C, which keeps Cdk1/cyclin B active. That mechanism represents a 
positive feedback loop, which escorts replicating cells through mitosis (Hoffmann et al, 
1993). 
Treatment with ABNM-13 led to up-regulation of Cdc25B levels which results in 
dephosphorylation and activation of Cdk1. The expression level of Cdc25C remained 
unchanged. However, Ara-C caused induction of Cdk1/cyclin B protein expression; 
simultaneous co-treatment with Ara-C and ABNM-13 induced an increase of Cdk1 expression 
level as well as increase of its activity. These observations showed that cell cycle arrest is 
induced by preventing entry into mitosis (Varmeh-Ziaie and Manfredi, 2007). 
Cdk2 protein level is regulated by Cdc25A and is needed for S-phase progression (Donzelli et 
al, 2002). Hence, the combination of Cdc25B overexpression and Cdc25A degradation 
resulted in a nearly complete S-phase arrest by treatment with 15µM ABNM-13 alone or in 
combination with 15nM Ara-C. 
ABNM-13 causes apoptosis in only 22% of all HL-60 cells (after 48 hours). This observation 
supports the conclusion that cell cycle inhibition rather than induction of apoptosis is the 
primary antineoplastic effect of this novel d agent. 
We therefore believe that a portion of treated cells was growing much slower than untreated 
controls, but did not undergo necrosis or apoptosis. Apoptosis was determined by the level of 
cleaved caspase 3 protein expression after 8 hours. Elevation of cleaved caspase 3 led to 
increase of γH2AX protein expression level after incubation with ABNM-13 for 24 hours. 
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These observations led us to the conclusion that treatment with ABNM-13 did not primarily 
cause DNA double strand breaks but rather was the result of caspase-3 induced DNAse 
activation. Supporting that theory, constitutive phosphor-ATM protein level remained 
unchanged.  
Cell death caused by mitotic catastrophe (i.e. the formation of giant cells with more than one 
nucleus) being induced by inhibition of Chk2 protein expression (Portugal et al, 2010; 
Castedo et al, 2004) could not be observed at any time point.  
Finally, ABNM-13 was combined with Ara-C, a well established first-line antitumor agent. 
Combination treatment is expected to produce fortified antitumor effects, if the 
pharmacokinetic and pharmacological properties are different from each other. Accordingly, 
ABNM-13, which disregulated dTTP and dGTP pools and Ara-C, which is known to affect 
dCTP pools (Gandhi et al, 1997; Wills et al, 2000; Seymour et al, 1996) inhibited cell 
proliferation synergistically.  Employing a sequential growth inhibition assay with ABNM-13 
and Ara-C, all 12 concentrations applied resulted in highly synergistic antineoplastic effects. 
ABNM-13 exerts pronounced anticancer activity as single drug as well as in combination with 
Ara-C. In addition, it has been shown that ABNM-13 acts as an effective RR inhibitor. Due to 
these promising results, we believe that further investigations and in vivo studies with this 
novel antitumor drug are warranted and we therefore consider ABNM-13 as a potent 
candidate for effective future cancer treatment options. 
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5.2. DIG 
 
Pancreatic cancer is a very aggressive, malignant neoplasm with poor prognosis and short 
survival rate. Digalloylresveratrol (DIG) is a novel synthetic ester of the natural compounds 
gallic acid and resveratrol and was suggested to exhibit promising antitumor activity in 
pancreatic cancer cells to possibly support conventional chemotherapy in the near future. 
Bernhaus et al demonstrated that growth inhibition of HT-29 colon cancer cells after 
treatment with DIG was superior to incubation with an equimolar combination of RV and GA 
(Bernhaus et al, 2009). In HL-60 cells the inhibition of cell proliferation of DIG also exceeded 
that of GA by 10-fold (Madlener et al, 2007). These results support the conclusion that the 
RV backbones, to which galloyl-residues are connected, are responsible for the determined 
additive effects (Madlener et al, 2010). 
Interestingly, clonogenic assays with DIG using three different pancreatic cancer cell lines 
(AsPC-1, BxPC-3, PANC-1) did not show any similar effects. Different cellular morphology 
and pharmacology might be an explanation for these surprising results. Furthermore, DIG was 
combined with dFdC, a well established first-line chemotherapeutic drug against pancreatic 
cancer. At the concentrations applied, no synergistic effects could be observed in AsPC-1 
cells. These results support the conclusion that DIG and dFdC do not affect cell proliferation 
in a different way as it was revealed with ABNM-13 and Ara-C. 
Recent investigations showed that DIG inhibits RR by chelating the tyrosyl radical being 
essential for RR activity (Madlener et al, 2007). The in vitro radical-scavenging activity of 
DIG exceeded the equimolar combination of RV and GA by about 2.5-fold. These results are 
in correlation with the measurement of RR in situ activity by 
14
C-cytidine assay. We could 
demonstrate that DIG significantly inhibited RR in situ activity in all pancreatic cell lines. 
In addition, DIG led to alterations of dNTP pool balance in AsPC-1 cells: dATP pools were 
significantly depleted while dCTP pools remained unchanged, and dTTP pools were 
marginally elevated. That imbalance of dNTP pools finally blocks DNA synthesis and 
subsequent cell proliferation. Perturbation of dNTP pools and inhibition of RR in situ activity 
are the consequences of treatment with DIG. These results are consistent with observations 
concerning the cell cycle regulation. DIG caused an S-phase arrest in AsPC-1 cells, which 
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confirms the fact that RR inhibition results in blocking the S-phase transit of proliferating 
cells (Chimploy et al, 2009). 
In contrast, treatment with DIG caused G2-M arrest in BxPC-3 cells while PANC-1 cells did 
not show any effect. 
It was demonstrated that DIG exhibits strong pro-apoptotic properties in HL-60 cells and 
triggers apoptosis by the caspase 3 pathway (Madlener et al, 2010). Apoptosis in pancreatic 
cell lines (AsPC-1 and PANC-1) upon treatment with DIG occurred only in a negligible rate 
of cells after 72 hours and accordingly, the expression level of caspase 3 protein in AsPC-1 
cells remained unchanged. These results indicate that DIG as well as ABNM-13 is rather an 
inhibitor of the cell cycle than an inducer of programmed cell death. 
Because of cell perturbations, checkpoint proteins are activated preventing DNA synthesis 
and halting cell cycle progression (Kastan and Bartek, 2004; Shiloh, 2003; Bartek and Lukas, 
2003). Cell cycle checkpoint effector kinases Chk1 and Chk2 are activated by ATR or ATM, 
respectively. It is believed that these protein kinases are activated in the presence of broken 
DNA double strands. Treatment with DIG in AsPC-1 cells shows an up-
regulation/phosphorylation of ATM, which indicates DNA double strand breaks. These 
observations indicate that ATM up-regulation is important in response of DNA alkylation and 
not limited to ionizing radiation-induced response (Ke-Qing and Suo-Jiang, 2003). 
DIG treatment led to activation of Chk2 in AsPC-1 cells, which was paralleled with 
phosphorylation of Cdc25A phosphatase at Ser177 and targeted it for protein degradation 
after 8 hours. Cdc25A is an oncogene and essential for cell cycle transit. 
Using AsPC-1 cells, western blot analysis of p38MAPK, Erk1/2, and Akt mitogen-activated 
protein kinases (MAPK) showed that DIG blocked Erk1/2 phosphorylation in the cytoplasma 
while inducing phosphorylation of p38 and Akt kinases. MAPK enzymes are important 
connections between cell surface receptors and critical regulatory targets. These enzymes 
answer to physical and chemical stress (e.g. chemotherapeutic substances) by regulating most 
cellular processes, from specific protein expression to programmed cell death (Johnson and 
Lapadat, 2002).  
Fenton et al also observed an inhibition of the Erk1/2 cytoplasmic pathway in a specific 
papillary thyroid cancer cell line after treatment with Sunitinib, an inhibitor of receptor 
tyrosine kinases. It is suggested that blocking this pathway is part of a mechanism, which 
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results in inhibition of cell proliferation and causes up-regulation of 	IS gene expression. 
Fenton and co-workers demonstrated that Sunitinib induces expression of sodium (Na)/iodide 
(I) symporters (NIS) (Fenton et al, 2010). 
Inhibition of Erk1/2 pathway in AsPC-1 after treatment with DIG may induce expression of a 
similar protein resulting in more effective cell regulation and homeostasis. 
DIG exhibits significant inhibition of the in situ RR activity, induction of cell cycle arrest, and 
a high in vitro radical-scavenging activity. Taken together, it could be demonstrated that DIG 
exerts promising anticancer effects in pancreatic cancer cells and may be of interest to 
preclinical investigations and in vivo studies.  
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6. Abstract 
 
The enzyme ribonucleotide reductase (RR) is essential for the conversion of ribonucleoside 
diphosphates into deoxyribonucleoside diphosphates, which are the basic units for DNA 
synthesis and DNA repair. De novo dNTP synthesis is an exactly regulated reaction, thus 
making RR the rate-limiting enzyme. Because of its up-regulation in malignant tumor cells, 
RR is considered to be a sensitive target for cytotoxic chemotherapeutic agents. 
In this diploma thesis, two different novel compounds were investigated for their anticancer 
activity in various human tumor cell lines. ABNM-13 is a novel designed N-hydroxy-N`-
aminoguanidine using 3D molecular space modeling techniques while Digalloylresveratrol 
(DIG) represents a novel synthetic ester of the polyhydroxy phenolic substances resveratrol 
(3,4,5-trihydroxystilbene; RV) and gallic acid (3,4,5-trihydroxybenzoic acid; GA). Both 
components of DIG are naturally occurring substances with promising results in cancer 
treatment. Biochemical effects of ABNM-13 were investigated in human HL-60 
promyelocytic leukemia cells whereas effects of DIG were evaluated in three different 
pancreatic cancer cell lines (AsPC-1, BxPC-3, and PANC-1). ABNM-13 as well as DIG were 
suggested to inhibit RR activity causing block of DNA replication, cell perturbations, 
induction of programmed cell death, and growth arrest. 
Indeed, both novel agents proved to be effective inhibitors of RR by significantly lowering the 
incorporation of 
14
C-labeled cytidine into DNA of tumor cells. Furthermore, both compounds 
caused alterations of dNTP pool balance and provoked cell cycle arrest and activation of cell 
cycle checkpoint effector kinases Chk1 and Chk2. Inhibition of RR activity results in 
activation of Chk1 and/or Chk2, leading to degradation of Cdc25A, which is responsible for 
cell cycle transit.  
ABNM-13 treatment of HL-60 cells further led to up-regulation of Cdc25B, which caused 
dephosphorylation and activation of Chk1. Dysregulation of both Cdc25A and Cdc25B 
induced cell cycle arrest in S-phase.  
Western blot analysis after treatment of AsPC-1 cells with DIG demonstrated that inhibition 
of RR activity causes replicative stress, which results in up-regulation of mitogen-activated 
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protein kinases p38 and Akt. Interestingly, an inhibition of Erk1/2 cytoplasmic pathway could 
also be observed. 
Our investigations also showed that the primary antineoplastic effect of DIG as well as 
ABNM-13 is rather inhibition of the cell cycle than induction of programmed cell death. 
ABNM-13 was then combined with Cytarabine (Ara-C), a first-line cytotoxic agent resulting 
in a synergistic potentiation of the antineoplastic effect of Ara-C. In contrast, DIG in 
combination with Gemcitabine (dFdC) did not show any synergistic effects. 
Due to these promising results, ABNM-13 and DIG may be potential candidates for further 
preclinical investigations and in vivo studies. 
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7. Zusammenfassung 
 
Ribonukleotid Reduktase (RR) ist ein Enzym, das für die Konvertierung von 
Ribonukleotiddiphosphaten in Desoxyribonukleotiddiposphate essentiell ist. Diese Bausteine 
bilden die Grundlage für DNA Synthese und DNA Reparatur. Die de novo dNTP Synthese 
stellt eine exakt regulierte Reaktion dar, weshalb RR hier als limitierendes Enzym fungiert. 
Zahlreiche Untersuchungen ergaben, dass die Expression von RR in Tumorzellen 
hochreguliert wird, wodurch dieses Enzym für zytotoxische chemotherapeutische Substanzen 
ein sensibles Ziel darstellt. 
Im Zuge dieser Diplomarbeit wurden zwei neue Substanzen untersucht, von welchen man sich 
in verschiedenen humanen Tumorzelllinien antikanzerogene Wirkung erhoffte. ABNM-13 ist 
ein neu synthetisiertes N-hydroxy-N`-aminoguanidin welches mittels 3D molecular space 
modeling Technikenentworfen wurde, um gezielt die RR Aktivität zu hemmen. 
Digalloylresveratrol (DIG) hingegen ist ein synthetisch hergestellter Ester, zusammengesetzt 
aus den natürlich vorkommenden polyhydroxyphenolischen Substanzen Resveratrol (3,4,5-
trihydroxystilbene; RV) und Gallussäure (3,4,5-trihydroxybenzoic acid; GA). Jede der beiden 
Einzelkomponenten zeigte bereits in früheren Untersuchungen vielversprechende Ergebnisse 
in der Krebsbehandlung. 
Die biochemische Wirkung von ABNM-13 wurde in humanen HL-60 Promyelozyten-
Leukämiezellen untersucht, wohingegen die Effekte von DIG in verschiedenen 
Pankreaskarzinomzelllinien (AsPC-1, BxPC-3, PANC-1) nachgewiesen werden sollten. 
Durch einen möglichen inhibierenden Effekt beider Substanzen auf die Aktivität der RR wäre 
eine Störung des Zellstoffwechsels die Folge, die in einer Hemmung der DNA Replikation, 
einem Arrest des Zellwachstums und möglicherweise Induktion von Apoptose resultiert. 
Sowohl ABNM-13 als auch DIG bewirkten aufgrund erster Untersuchungen tatsächlich eine 
signifikante Hemmung der RR Aktivität, was durch die Abnahme des Einbaus von 
14
C-
markiertem Cytidin in die DNA von Tumorzellen gezeigt werden konnte. Des Weiteren 
konnte demonstriert werden, dass die ausgewogene Verteilung der dNTP Pools durch die 
Behandlung mit ABNM-13 und DIG verändert wird. Beide Substanzen greifen in die 
Regulation des Zellzyklus ein, was schließlich zur Aktivierung der spezifischen Checkpoint 
Effektorkinasen Chk1 und Chk2 führt. Durch die Hemmung der RR Aktivität wird Chk1 
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und/oder Chk2 aktiviert, was wiederum den Abbau von Cdc25A bewirkt. Cdc25A ist ein 
Onkogen, das beim Zellzyklus-Transit von entscheidender Bedeutung ist. 
Die Behandlung von HL-60 Zellen mit ABNM-13 bewirkt zusätzlich eine Erhöhung des 
Cdc25B Proteinlevels, was Dephosphorylierung und Aktivierung von Chk1 zur Folge hat. 
Durch diese Dysregulation von Cdc25A und Cdc25B kann in HL-60 Zellen in weiterer Folge 
ein S-Phase Arrest beobachtet werden. 
Western Blot Analysen nach Behandlung in AsPC-1 Zellen mit DIG zeigten, dass eine 
Hemmung der RR Aktivität die Erhöhung des Expressionslevels von mitogen-aktiverenden 
Proteinkinasen p38 und Akt bewirkt. Im Gegensatz dazu wurde allerdings auch eine 
Hemmung des zytoplasmatischen Erk1/2 Signalweges beobachtet. 
Interessanterweise induzieren beide Substanzen nur in sehr geringem Maße Apoptose. Das 
legt den Schluss nahe, dass sowohl ABNM-13 als auch DIG eher hemmend auf den 
Zellzyklus als induzierend auf den programmierten Zelltod wirken.  
Schließlich wurde gezeigt, dass ABNM-13 in Kombination mit Cytarabine (Ara-C), einem 
bewährten „first-line“ Zytostatikum, zu einer signifikanten Verstärkung des 
antineoplastischen Effekts von Ara-C führt. Im Gegensatz dazu konnte DIG in Kombination 
mit Gemcitabine (dFdC) keinen ähnlichen Effekt erzielen. 
Aufgrund dieser vielversprechenden Ergebnisse und Erkenntnisse könnten ABNM-13 und 
DIG zu potentiellen Anwärtern für etwaige präklinische Untersuchungen oder in vivo Studien 
werden. 
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